

**XII International Symposium on Amyloidosis**  
**‘From Molecular Mechanisms Toward the Cure of Systemic Amyloidoses’**  
**Crowne Plaza Rome – St. Peter’s**  
**Rome**  
**April 18–21, 2010**

**Programme**

**Sunday, April 18**

**Sunday, April 18**  
**10:00**

Registration opens

**Sunday, April 18**  
**15:00–17:00**

**Sponsored workshops**

**Hall Fori Imperiali**

**15:00–16:00 FoldRx workshop**

Tafamidis, Disease Modifying Treatment for TTR Amyloidosis  
Development, Programme Overview and Future Initiatives

Chairperson: Donna Grogan

1. Longitudinal and Cross Sectional Studies of ATTR Disease Progression
  - TTR Amyloid Cardiomyopathy (R. Falk)
  - TTR Amyloid Polyneuropathy (T. Coelho)
2. Long-term Effects of Tafamidis – Top Line Results and Future Plan
  - Disease Modifying Effects of Tafamidis at 18 and 30 Months (T. Coelho)
  - THAOS, a Patient Outcome Survey to Study Longer Term Effects of Tafamidis (T. Coelho)
3. Future Initiatives
  - Role of Tafamidis Post Liver Transplantation (V. Planté-Bordeneuve)
  - Identification of Asymptomatic Markers of Disease (V. Planté-Bordeneuve)

**16:00–17:00 Binding Site workshop**

Chairman: Robert Kyle

- Diagnosis of Amyloid Using FLC (P.N. Hawkins)
- Monitoring of Amyloid Using FLC (R.L. Comenzo)
- Potential Utility of Hevylite Analysis (A.R. Bradwell)

**Sunday, April 18**  
**17:30**

**Opening ceremony**

Welcome address from authorities

**Hall Fori Imperiali**

Giampaolo Merlini: Welcome and Introduction to the Symposium

Bouke Hazenberg: In Memoriam Enno Mandema

**Opening lectures**

Massimo Ceresa: *Magnificent Medicine, Historic Places of Care and Knowledge in Rome*

Robert A. Kyle: *Amyloidosis: A Brief History*

**Sunday, April 18**  
**19:30**

**Welcome party**

**Sunday, April 18**  
**20:00–22:00**  
**Flaminia Room**

**Meeting of the Board of Directors of the International Society of Amyloidosis**

**Monday, April 19**

**Monday, April 19**  
**8.00–8:30**  
**Hall Fori Imperiali**

**Introductory Lecture to the Symposium**

Chris Dobson: *Life on the edge: protein misfolding and disease from the test tube to the cell*

**Monday, April 19**  
**8:30–11:00**  
**Hall Fori Imperiali**

**Plenary session**

**Basic mechanisms: Fibril formation**

Chairmen: Robert Kisilevsky and Fabrizio Chiti

8.35–8.50 Robert Kisilevsky: *State of the art*

OP 1. *Heparan sulphate activates a histidine molecular switch that drives serum amyloid A aggregation and fibrillogenesis*

E. Elimova, R. Kisilevsky, J.B. Ancsin  
(Kingston, ON, Canada)

OP 2. *Amyloid formation by human muscle acylphosphatase in the presence of heparan sulphate*

N. Motamedi-Shad, E. Monsellier, L. Botti, S. Torrassa, A. Relini, F. Chiti  
(Florence and Genoa, Italy)

OP 3. *Effects of disease-associated mutations on the aggregation process of the 93-residue N-terminal fragment of human apolipoprotein A-I*

S. Raimondi, F. Guglielmi, S. Giorgetti, S. Di Gaetano, A. Arciello, A. Relini, S.M. Doglia, A. Natalello, P. Pucci, P. Mangione, L. Obici, G. Merlini, M. Stoppini, G.G. Tartaglia, M. Vendruscolo, R. Piccoli, V. Bellotti  
(Pavia, Naples, Genoa, Milan, Rome, Italy and Cambridge, UK)

OP 4. *Heparan sulphate/heparin binds transthyretin and promotes its fibrillogenesis*

F. Noborn, P. O'Callaghan, I. Dacklin, J.B. Ancsin, A. Damas, E. Lundgren, R. Kisilevsky, P. Westermark, J-P. Li  
(Uppsala, Sweden, Kingston, ON, Canada, Porto, Portugal)

OP 5. *Role of glycosaminoglycan sulphation in the formation of immunoglobulin light chain amyloid fibrils*

R. Ren, K.L. Laporte, M. Skinner, D.C. Seldin, C.E. Costello, L.H. Connors, V. Trinkaus-Randall  
(Boston, MA, USA)

**9:50–10:10 Coffee break**

OP 6. *Toward a comprehension of functional aggregation into amyloids in pituitary secretory granules*

A. Soragni, S.K. Maji, R. Riek  
(Zurich, Switzerland and Mumbai, India)

OP 7. *Genotype–phenotype correlation of TGF $\beta$ 1-linked corneal dystrophies in France: from clinical, histological and genetic findings to in situ X-ray diffraction data of corneal deposits*

S. Valleix, F. Briki, F. Niel, M. Boimard, B. Nedelec, M. Savoldelli, J.L. Bourges, G. Renard, C. Hamel, M. Delpech, B. Delbosc, B. Kantelip  
(Paris, France)

OP 8. *Molecular basis of amyloid fibril recognition through the conformation-sensitive B10 antibody fragment*

I. Morgado, C. Haupt, C. Parthier, H.A. Scheidt, M. Bereza, K. Wieligmann, D. Huster, M.T. Stubbs, U. Horn, M. Fändrich  
(Halle, Leipzig and Jena, Germany)

10:45–11:00 Fabrizio Chiti: *Perspectives*

**Monday, April 19**  
**11:00–12:30**  
**Hall Fori Imperiali**

**Plenary session**

**Basic mechanisms: Cell toxicity and repair**

Chairmen: Massimo Stefani and Joel Buxbaum

11:00–11:15 Massimo Stefani: *State of the art*

OP 9. *Histopathologic and serologic evidence for a role of the molecular chaperone clusterin in amyloidotic cardiomyopathy*

M.J. Greene, P. Soo Hoo, K. Laporte, D. Seldin, L.H. Connors  
(Boston, MA, USA)

OP 10. *Transthyretin channel formation in lipid membranes: Implications for pathogenesis*

Y. Hirakura, R. Azimov, R. Azimova, B.L. Kagan  
(Los Angeles, CA, USA)

OP 11. *Cellular toxicity of soluble amyloidogenic light chains correlates with patient survival*

L.A. Sikkink, M. Ramirez-Alvarado  
(Rochester, MN, USA)

OP 12. *AL amyloidosis: the repertoire of immunoglobulin  $\lambda$  light chains causing predominant cardiac involvement and identification of a preferentially involved germline gene, IGLV1-44*

V. Perfetti, S. Casarini, G. Palladini, P. Rognoni, L. Obici, S. Perlini, G. Merlini  
(Pavia, Italy)

OP 13. *Repair of damaged mesangium by rat mesenchymal stem cells (RMSCs) in a 6D living cell model*

G.A. Herrera, E.A. Turbat-Herrera, J. Teng  
(Tempe, AZ, USA)

12:15–12:30 Joel Buxbaum: *Perspectives*

**Monday, April 19**  
**12:30–14:00**

**Lunch and poster viewing**

**Monday, April 19**  
**14:00–16:00**  
**Hall Fori Imperiali**

**Plenary session**

**Animal models**

Chairpersons: Maria J. Saraiva and Adriano Aguzzi

14:00–14:15 Maria J. Saraiva: *State of the art*

OP 14. *Fly model of type 2 diabetes: Processing of proIAPP makes a difference*  
S.W. Schultz, K.P.R. Nilsson, S. Thor, G.T. Westermark  
(Linköping, Uppsala, Sweden)

OP 15. *Human serum amyloid A expression in C-elegans*

G.T. Westermark, J. Sponarova, A. Vahdat Shariatpanahi, P. Westermark  
(Uppsala, Linköping, Sweden)

OP 16. *Controllable expression of SAA in transgenic mice: a refined model of systemic amyloidosis*

P. Simons, R. Al-Shawi, S. Ellmerich, I. Slamova, K.G. Bodin, S. Minogue, M.B. Pepys, P.N. Hawkins  
(London, UK)

OP 17. *A transgenic mouse model of human systemic amyloidosis*

M.D. Benson, A.D. Kalopissis, M. Charbert, J.J. Liepnieks, B. Kluge-Beckerman  
(Indianapolis, IN, USA and Paris, France)

- OP 18. *Carvedilol treatment reduces transthyretin deposition in a familial amyloidotic polyneuropathy mouse model*  
B. Macedo, A.R. Batista, J. Magalhães, M.J. Saraiva  
(Porto, Portugal)
- OP 19. *Analyses of vervet monkeys suffering from ATTR amyloidosis: A candidate model animal for human TTR-related amyloidosis*  
M. Ueda, N. Ageyama, S. Nakamura, J.K. Chambers, Y. Misumi, R. Nakaguma, S. Shinriki, M. Shono, H. Jono, K. Obayashi, Y. Une, Y. Ando  
(Kumamoto, Ibaraki, Shiga and Kanagawa, Japan)
- OP 20. *Transthyretin as amyloid precursor and amyloid inhibitor in transgenic mice: Location counts*  
J. Buxbaum, N. Reixach, X. Li, F. Cattaneo, E. Maslah  
(La Jolla, CA, USA)

15:40–16:00 Adriano Aguzzi: *Perspectives*

**Monday, April 19**  
**16:00–17:30**

**Poster viewing (refreshments available during poster viewing)**

*Poster Award Committee: Jean Sipe (coordinator), Ana Damas, Genaro Esposito, Gilles Grateau, Gunilla Westermark*

**Poster Group 1**

- PP 1. *Lysophospholipids and non-esterified fatty acids induce the extension of  $\beta$ 2-microglobulin-related amyloid fibrils at neutral pH*  
K. Hasegawa, T. Ookoshi, H. Kimura, N. Takahashi, H. Yoshida, R. Miyazaki, Y. Goto, H. Naiki  
(Fukui and Osaka, Japan)
- PP 2. *Ligand-binding properties of human transthyretin*  
M. Pinto, D. Blasi, J. Nieto, G. Arsequell, G. Valencia, A. Planas, J. Quintana, N.B. Centeno  
(Barcelona, Spain)
- PP 3. *Binding by serum amyloid P component (SAP) is a pathognomonic feature of genuine amyloid fibrils*  
G.A. Tennent, M.B. Pepys  
(London, UK)
- PP 4. *The SUMO fusion technology for synthesis of pathogenic immunoglobulin light chains*  
V. Perfetti, P. Rognoni, S. Casarini, G. Palladini, G. Merlini  
(Pavia, Italy)
- PP 5. *Doxycycline affects association and folding of  $\beta$ 2-microglobulin*  
K. Pagano, A. Corazza, F. Fogolari, P. Viglino, S. Giorgetti, S. Raimondi, M. Stoppini, V. Bellotti, G. Esposito  
(Udine and Pavia, Italy)
- PP 6. *The critical role of the constant region in immunoglobulin light chain thermal stability and aggregation*  
E.S. Klimtchuk, O. Gursky, R.S. Patel, K.L. Laporte, L.H. Connors, M. Skinner, D.C. Seldin  
(Boston, MA, USA)
- PP 7. *Morphological and functional differences of aldehyde-induced alpha-synuclein oligomers*  
T. Näsström, T. Wahlberg, M. Barbu, V. Silva, M. Karlsson, F. Nikolajeff, L. Lannfelt, M. Ingelsson, J. Bergström  
(Uppsala, Sweden)

**Monday, April 19**  
**16:00–17:30**

- PP 8.  *$\beta$ 2-m tryptophanes as independent evolutive responses are alternative players of amyloidogenesis*  
S. Raimondi, N. Barbarini, S. Giorgetti, P. Mangione, R. Porcari, G. Esposito, I. Zorzoli, A. Gallanti, L. Marchese, M. Stoppini, V. Bellotti (Pavia and Udine, Italy)
- PP 9. *Affinity of SAA with HDL may partially interpret SAA1 polymorphism related AA amyloidogenesis*  
T. Yamada, J. Sato, Y. Okuda (Tochigi and Ehime, Japan)
- PP 10. *Given prominence of the direct implication of aluminium and OH<sup>-</sup> radical on the A $\beta$ /chondroitin sulphate binding*  
N. Magy, Y.C. Guillaume, L. Excoffon, C. André (Besançon, France)
- PP 11. *Acute-phase serum amyloid A is present in human colostrum and milk*  
Y. Kumon, Y. Yasuoka, S. Yamanaka, A. Takeuchi, T. Sugiura (Kochi, Japan)
- PP 12. *NMR relaxation study of  $\beta$ 2-microglobulin*  
D. Gümral, F. Fogolari, A. Corazza, P. Viglino, S. Giorgetti, M. Stoppini, V. Bellotti, G. Esposito (Udine and Pavia, Italy)

#### **Poster Group 2**

- PP 13. *Transfer of IAPP amyloid between murine beta cells*  
M.E Oskarsson, G.T. Westermark (Uppsala, Sweden)
- PP 14. *The VLITL aggregation-prone motif might trigger amyloid fibril formation of fibrinogen A $\alpha$ -chain frameshift variants in vivo*  
S. Valleix, P. Derreumaux, C. Garnier, F. Briki, M. Boimard, J. Doucet, N. Rioux-Leclercq, L. Martin, G. Grateau, M. Delpech, P. Le Pogamp (Paris, France)
- PP 15. *Camelid single-domain antibodies as a therapeutic approach for Familial Amyloidosis of the Finnish type (FAF)*  
W. Van Overbeke, M. Guaraldo, J. Vanderkerckhove, A. De Ganck, J. Gettemans (Ghent, Belgium)
- PP 16. *Relationship between amyloid deposition and cell death in familial amyloidotic polyneuropathy*  
O. Toshinori, Y. Misumi, Y. Ando, M. Ueda, K. Obayashi, H. Jono, Y. Su, T. Yamashita, M. Uchino (Kumamoto, Japan)
- PP 17. *Age-dependent increase in thiol conjugated forms of transthyretin (TTR) in the elderly: quantitative analyses by the SELDI-TOF MS protein chip system*  
S. Kawahara, M. Ueda, A. Miyazaki, U. Yuki, Y. Horibata, H. Jono, K. Obayashi, K. Ikeda, S. Tanase, Y. Ando (Kumamoto, Japan)
- PP 18. *Mechanistic and structural aspects of the interaction of luminescent conjugated polymers with amyloid oligomers*  
S. Hornemann, J. Sponarova, C. Zhu, V. Finder, R. Glockshuber, P.K. Nilsson, A. Aguzzi (Zurich, Switzerland and Linköping, Sweden)
- PP 19. *Proteasome activity and stress in light chain amyloidosis*  
L. Oliva, N. Pengo, G. Palladini, P. Cascio, E. Pasqualetto, G. Merlini, R. Sitia, S. Cenci (Milano, Pavia and Torino, Italy)
- PP 20. *Distribution of macrophages in spleen with amyloid*  
A. Vahdat Shariatpanahi, K. Lundmark, G.T. Westermark (Linköping and Uppsala, Sweden)

**Monday, April 19**  
**16:00–17:30**

- PP 21. *Antioxidative effect of albumin on transthyretin-related amyloidosis*  
J. Guo, H. Jono, T. Kugimiya, S. Saito, T. Maruyama, Y. Misumi,  
Y. Hoshii, Y. Su, M. Ueda, M. Otagiri, Y. Ando  
(Kumamoto and Ube, Japan)
- PP 22. *Production, purification and aggregation of IgE  $\lambda$  light chain fragment*  
P. Arosio, T. Müller-Späth, H. Wu, M. Morbidelli, A. De Luigi,  
M. Salmona  
(Zurich, Switzerland and Milan, Italy)
- PP 23. *Amyloid fibrils formed by selective N-, C-terminal sequences of mouse apolipoprotein A-II*  
J. Sawashita, F. Kametani, K. Hasegawa, M. Mori, H. Naiki, K. Higuchi  
(Shinshu, Tokyo and Fukui, Japan)
- PP 24. *TTR assembly of annular oligomers that associate laterally precede the appearance of amyloid protofibrils*  
R.H. Pires, Á. Karsai, M.J. Saraiva, A.M. Damas, M. Kellermayer  
(Budapest, Hungary and Porto, Portugal)

**Poster Group 3**

- PP 25. *Targeting transthyretin–X-ray crystallography and rational drug design*  
A.J. Morrison, A.J.A. Cobb, A. Coyne, R. Gill, M.D. Smith, S.V. Ley,  
S.P. Wood, M.B. Pepys  
(London, UK)
- PP 26. *Molecular mechanisms of transthyretin regulation in neurons*  
F. Cattaneo, X. Li, J. Hulleman, J. Buxbaum  
(La Jolla, CA, USA)
- PP 27. *Epigallocatechin-3-gallate (EGCG) binds to TTR and modulates its amyloidogenicity*  
N. Ferreira, I. Cardoso, M.R. Domingues, R. Vitorino, M. Bastos,  
G. Bai, M.J. Saraiva, M.R. Almeida  
(Porto and Aveiro, Portugal)
- PP 28. *A novel anti-amyloid chaperone*  
J. Johansson, H. Willander, K. Nordling, M. Fitzen, C. Nerelius,  
J. Presto  
(Uppsala, Sweden)
- PP 29. *Transthyretin V30M forms two compositionally distinct amyloid fibrils which correlate to clinicopathology and liver transplantation outcome*  
E. Ihse, O.B. Suhr, U. Hellman, P. Westermark  
(Uppsala and Umeå, Sweden)
- PP 30. *Amyloidogenic light chains internalize and aggregate in cardiomyocytes*  
D.O. Olatoye, E.G. Randles, M. Ramirez-Alvarado  
(Rochester, MN, and Boston, MA, USA)
- PP 31. *Occurrence and nature of amyloid in atherosclerotic aorta and calcified heart valves*  
S. Enqvist, K. Sletten, U. Hellman, E. Wassberg, L. Eriksson,  
P. Westermark  
(Uppsala, Sweden and Oslo, Norway)
- PP 32. *Drug discovery targeted at transthyretin cardiac amyloidosis: rational design, synthesis and biological activity of new transthyretin amyloid inhibitors*  
D. Blasi, M. Pinto, J. Nieto, G. Arsequell, G. Valencia, A. Planas,  
N.B. Centeno, J. Quintana  
(Barcelona, Spain)
- PP 33. *Serum amyloid P component is a constituent of normal adult mammalian glomeruli*  
W.L. Hutchinson, J. Herbert, M.B. Pepys  
(London, UK)

**Monday, April 19**  
**16:00–17:30**

**Poster Group 4**

- PP 34. *Quantitative analysis of amyloid mass in mice by image segmentation*  
J.S. Wall, T. Richey, A. Stuckey, S.J. Kennel, A. Solomon  
(Knoxville, TN, USA)
- PP 35. *Rapid dehalogenation of <sup>124</sup>I-SAP in mice enhances the specific detection of amyloid: A dynamic microPET imaging study*  
J.S. Wall, T. Richey, A. Stuckey, A. Solomon, S.J. Kennel  
(Knoxville, TN, USA)
- PP 36. *Immunoinaging of AA amyloid using a novel amyloid-specific tracer*  
J.S. Wall, T. Richey, A. Stuckey, P. Seubert, R. Barbour, D. Schenk,  
A. Solomon, S.J. Kennel  
(Knoxville, TN and South San Francisco, CA, USA)
- PP 37. *The influence of SAA on ATP binding cassette A1 and G1 mRNA levels in cholesterol laden macrophages*  
S.P. Tam, R. Kisilevsky  
(Kingston, ON, Canada)
- PP 38. *Chain reaction of amyloid fibril formation with induction of basement membrane in FAP*  
Y. Misumi, Y. Ando, M. Ueda, K. Obayashi, H. Jono, Y. Su,  
T. Yamashita, M. Uchino  
(Kumamoto, Japan)
- PP 39. *ApoA-I oligomers generated by heparan sulphate remodeling of HDL-SAA promote cholesterol efflux*  
S.P. Tam, R. Kisilevsky, J.B. Ancsin  
(Kingston, ON, Canada)
- PP 40. *A single mutation promotes amyloidogenicity through a highly promiscuous dimer interface*  
M. Ramirez-Alvarado, F.C. Peterson, E.M. Baden, B.A.L. Owen,  
B.F. Volkman  
(Rochester, MN and Milwaukee, WI, USA)
- PP 41.  *$\alpha$ B-crystallin (HspB5) in familial amyloidotic polyneuropathy*  
J. Magalhães, S. Duque Santos, M.J. Saraiva  
(Porto, Portugal)
- PP 42. *Scanning/transmission electron microscopy to study how amyloid fibrils are extruded into the matrix*  
G.A. Herrera, J. Teng, E.A. Turbat-Herrera  
(Tempe, AR, USA)
- PP 43. *Animal model of AL-amyloidogenesis recapitulates in vitro findings*  
G.A. Herrera, E.A. Turbat-Herrera, J. Teng  
(Tempe, AR, USA)
- PP 44. *Structural and functional analysis of amyloid fibril formation by two closely related light chains*  
M. Ramirez-Alvarado, D.J. Martin  
(Rochester, MN, USA)

**Poster Group 5**

- PP 45. *The low plasma concentration of amyloidogenic apolipoprotein A-I can be explained by a reduced efficiency of its cellular secretion*  
M. Marchesi, C. Parolini, C. Valetti, P. Mangione, L. Obici, S. Giorgetti,  
S. Raimondi, S. Donadei, G. Gregorini, G. Merlini, M. Stoppini,  
G. Chiesa, V. Bellotti  
(Milan, Genoa, Pavia and Brescia, Italy)
- PP 46. *Light chain deamidation in AL $\lambda$  amyloid-associated proteins*  
M. Eulitz, C. Murphy, D. Weiss, A. Solomon  
(Knoxville, TN, USA)

**Monday, April 19**  
**16:00–17:30**

- PP 47. *Proteomic characterization of amyloid deposits in transthyretin amyloidosis associated with various mutations*  
V. Valentini, F. Lavatelli, L. Obici, S. Donadei, S. Perlini, G. Palladini, G. Merlini  
(Pavia, Italy)
- PP 48. *Mass spectrometry-based proteomics as a diagnostic tool when immunoelectron microscopy fails in typing amyloid deposits*  
F. Lavatelli, V. Valentini, G. Palladini, L. Verga, P. Russo, A. Foli, L. Obici, G. Sarais, V. Perfetti, S. Casarini, G. Merlini  
(Pavia, Italy)
- PP 49. *Mass spectrometry-based proteomic analysis of iatrogenic insulin mediated amyloidosis (AIns)*  
A. Dogan, J.A. Vrana, J.D. Theis, J.D. Gamez, P.J. Kurtin, K.L. Grogg  
(Rochester, MN, USA)
- PP 50. *Inhibitory effects of anti-IL-1 beta antibody in murine AA amyloidosis model*  
S. Murata, M. Ueda, Y. Tanabe, N. Kurata, N. Demura, H. Gram, M. Tasaki, Y. Su, H. Jono, M. Shono, K. Obayashi, Y. Ando  
(Kumamoto and Tokyo, Japan and Basel, Switzerland)
- PP 51. *Neurologic and metabolic phenotypes in an AL amyloidosis transgenic mouse model*  
J.E. Ward, P. SooHoo, G. Tordaldo, R. Jasuja, L.H. Connors, C. O'Hara, D.C. Seldin  
(Boston, MA, USA)
- PP 52. *Depletion of macrophages influences amyloid deposition in spleen*  
K. Lundmark, A. Vahdat Shariatpanahi, P. Westermark, G.T. Westermark  
(Linköping and Uppsala, Sweden)
- PP 53. *Mouse ApoA-II amyloid fibrils deposit in skeletal muscle and exhibit amyloidosis-enhancing activity*  
K. Higuchi, J. Qian, J. Yan, F. Ge, B. Zhang, X. Fu, H. Tomozawa, J. Sawashita, M. Mori  
(Matsumoto, Japan)
- PP 54. *Strategies to modelize AL amyloidosis in mouse*  
C. Sirac, S. Bender, F. Bridoux, A. Jaccard, C. Lacombe, G. Touchard, M. Cogné  
(Limoges, France)
- PP 55. *Dose ranging and efficacy study of low-dose doxycycline/TUDCA in FAP mouse models*  
I. Cardoso, D. Martins, T. Ribeiro, G. Merlini, M.J. Saraiva  
(Porto, Portugal and Pavia, Italy)

**Poster Group 6**

- PP 56. *AA amyloidosis: Potential therapy with antisense oligonucleotides*  
B. Kluge-Beckerman, M.D. Benson  
(Indianapolis, IN, USA)
- PP 57. *Kidney transplantation in AA amyloidosis*  
T.N. Wien, T. Leivestad, A.V. Reisæter, A. Foss, A. Hartmann  
(Oslo, Norway)
- PP 58. *The p.Ala154fsX47 ApoAI frameshift variant is a novel disulfide-linked ApoAI*  
F. Bridoux, G.A. Tennent, S. Delbes, E. Desport, C. Lacombe, A. Kalopissis, D. Rowczenio, M. Boimard, J.M. Goujon, G. Touchard, S. Valleix  
(Poitiers, France, London, UK and Paris, France)



**Monday, April 19**  
**16:00–17:30**

- PP 59. *Hereditary systemic amyloidosis associated with three novel apolipoprotein AI variants*  
D.M. Rowczenio, H.J. Lachmann, S.D.J. Gibbs, J.A. Gilbertson, T. Hunt, T.L. Russell, P.T. Sattianayagam, H. Trojer, A.D. Wechalekar, C.J. Whelan, P.N. Hawkins, J.D. Gillmore  
(London, UK)
- PP 60. *Rapidly progressive AA cardiomyopathy*  
W. Ishii, B. Kluge-Beckerman, J.J. Liepnieks, S.T. Vakili, M.D. Benson  
(Indianapolis, IN, USA)
- PP 61. *Nature of Os labrum-associated amyloid deposits*  
C. Murphy, S. Wang, S. Macy, J. Makovitzky, N. Athanasou, P. Westermark, D. Weiss, A. Solomon  
(Knoxville, TN, USA, Heidelberg, Germany, Oxford, UK and Uppsala, Sweden)
- PP 62. *Serum levels of soluble receptor for advanced glycation end products in AA amyloidosis are increased and related to loss of renal function*  
H.L.A. Nienhuis, J. Bijzet, R. Bos, C.G.M. Kallenberg, M. Bijl, B.P.C. Hazenberg  
(Groningen, The Netherlands)
- PP 63. *Clinical and genetic features of familial Mediterranean fever in Japan*  
A. Tsuchiya-Suzuki, Y. Masahide, A. Nakamura, K. Yamazaki, K. Agematsu, M. Matsuda, S.I. Ikeda  
(Matsumoto, Japan)
- PP 64. *Do inflammatory rheumatic diseases still cause as much harm through amyloidosis?*  
J. Hunter, L. McGregor  
(Glasgow, Scotland, UK)
- PP 65. *The diagnosis challenge of cerebral amyloid angiopathy: case series*  
M. Di Girolamo, S. Vollaro, D. Landi, F. Passarelli, P.M. Rossini, D. Lupoi  
(Rome, Italy)
- PP 66. *Systemic reactive (AA) amyloidosis in the course of common variable immunodeficiency*  
L. Serusi, M.M. Lorrain, A. Frau, G. Murgia, M.P. Barca, F. Collu, S. Spiga, M.M. Peralta, P.E. Manconi  
(Cagliari, Italy)
- PP 67. *The influence of some polymorphisms on development of AA amyloidosis*  
Z. Potysova, R. Rysava, V. Tesar  
(Prague, CZ)
- PP 68. *Early diagnostics of kidney damage in longstanding rheumatoid arthritis and amyloidosis*  
A. Tishko, S.V. Lapin, T.V. Vavilova, A.A. Totolian  
(Saint-Petersburg, Russia)
- PP 69. *Nodular localized cutaneous amyloidosis: a case report and review of literature*  
G. Giglio, G. Antuzzi, F. Carrozza, M. Musacchio, A. Antrilli, G. Palladini  
(Campobasso and Pavia, Italy)
- PP 70. *Amyloidosis and renal involvement: clinical course and prognosis*  
M.G. Chiappini, M. Di Girolamo, A. Grosso, L. Muzi  
(Rome, Italy)

**Poster Group 7**

- PP 71. *Localised amyloid at injection sites derived from porcine and human insulin*  
J.A. Gilbertson, T. Hunt, A.D. Wechalekar, H.J. Lachmann, P.N. Hawkins, J.D. Gillmore  
(London, UK)

**Monday, April 19**  
**16:00–17:30**

- PP 72. *Lysozyme amyloidosis (ALys) affecting a family with a new variant of lysozyme gene (LYZ) and hereditary hemorrhagic telangiectasia*  
M.Q. Lacy, J.D. Theis, J.A. Vrana, S. Madan, L. Frederick, D.S. Viswanathan, M.A. Gertz, A. Dogan  
(Rochester, MN, USA)
- PP 73. *Report and recommendations from the 1st International Workshop on the Hereditary Renal Amyloidoses, FAP Symposium, London 2008*  
A.J. Stangou, L. Lobato, S. Zeldenrust, B. Portmann, R. Linke, G. Otto, H. Wilczek, O. Suhr, D. Azoulay, G. Grateau, M. Picken, J. O'Grady, B.G. Ericzon, N. Heaton, M.D. Benson  
(London, UK, Porto, Portugal, Rochester, MN, USA, Martinsried, Germany, Mainz, Germany, Huddinge, Sweden, Umeå, Sweden, Villejuif, France, Paris, France, Chicago, IL, USA and Indianapolis, IN, USA)
- PP 74. *Non-hereditary apolipoprotein AI-associated pulmonary amyloid*  
D. Kestler, C. Murphy, D. Weiss, A. Solomon  
(Knoxville, TN, USA)
- PP 75. *Assessment of cardiac structural and functional alterations in APO A-I amyloidosis (Leu75Pro)*  
M. Salvetti, M.L. Muiesan, A. Paini, C. Agabiti Rosei, C. Aggiusti, D. Stassaldi, F. Beschi, L. Obici, A. Negrinelli, M. Nardi, G. Gregorini, G. Cancarini, E. Agabiti Rosei  
(Brescia and Pavia, Italy)
- PP 76. *Renal transplantation for homozygous AGel amyloidosis: a 21-year follow up*  
C.P.J. Maury  
(Helsinki, Finland)
- PP 77. *Assessment of arterial stiffness and vascular alterations in APO A-I amyloidosis (Leu75Pro)*  
A. Paini, M.L. Muiesan, M. Salvetti, C. Agabiti Rosei, C. Aggiusti, F. Bertacchini, F. Beschi, L. Obici, A. Negrinelli, G. Gregorini, G. Cancarini, E. Agabiti Rosei  
(Brescia and Pavia, Italy)
- PP 78. *Leu75Pro apolipoprotein A-I amyloidosis: prevalence and clinical features of liver involvement*  
L. Biasi, K. Prestini, M. Mendeni, A. Negrinelli, T. Scalvini, L. Obici, G. Gregorini, G. Merlini  
(Brescia and Pavia, Italy)
- PP 79. *Fibrinogen A  $\alpha$ -chain amyloidosis: phenotypic characterization and the role of liver transplantation*  
A.J. Stangou, N.R. Banner, B.M. Hendry, M. Rela, B. Portmann, J. Wendon, M. Monaghan, P. MacCarthy, M. Buxton-Thomas, C.J. Mathias, J.J. Liepnieks, J. O'Grady, N.D. Heaton, M.D. Benson  
(London, UK and Indianapolis IN, USA)
- PP 80. *Mutation in APOA1 predicts increased risk of ischemic heart disease and mortality without low HDL cholesterol*  
C.L. Haase, R. Frikke-Schmidt, B.G. Nordestgaard, A.K. Kateifides, D. Kardassis, L. B. Nielsen, A.H. Johnsen, P. Grande, V.I. Zannis, A. Tybjærg-Hansen  
(Copenhagen, Denmark, Heraklion, Greece and Boston, MA, USA)

**Monday, April 19**  
**17:30–19:00**  
**Rooms Flaminia**  
**and Marzia**

**Meetings of working groups and committees**

**Monday, April 19**  
**19:00–20.30**

**Dinner**

**Monday, April 19**  
**20.30–21.50**  
**Hall Fori Imperiali**

**Consensus Panels discussion**

20:30–21:10

**How to diagnose amyloidosis and type amyloid deposits**

Chairpersons: Maria Picken and Per Westermark

*Current practice for amyloid detection and typing*

M.M. Picken, P. Westermark

(Chicago, IL, USA and Uppsala, Sweden)

21:10–21:50

**Assessment of organ involvement and response to therapy in AL amyloidosis**

Chairmen: Morie A. Gertz and Giampaolo Merlini

*Definition of organ involvement and response to treatment in AL amyloidosis: an updated consensus opinion*

M.A. Gertz, G. Merlini for the AL amyloidosis Consensus Group

(Rochester, MN, USA and Pavia, Italy)

**Tuesday, April 20**

**Tuesday, April 20**  
**8.00–10.35**  
**Hall Fori Imperiali**

**Plenary session**

**Targeted molecules and gene therapy**

Chairmen: Jeffery W. Kelly and Merrill D. Benson

OP 21. *Novel palindromic ligands cementing the native quaternary structure of transthyretin*

P. P. Mangione, V. Bellotti, S. Deroo, G.W. Taylor, M.G. McCammon, C.V. Robinson, G.A. Tennent, M.D. Smith, A.J. Morrison, A.J.A. Cobb, A. Coyne, S.V. Ley, S.W. Wood, M.B. Pepys  
(London, Cambridge and Oxford, UK, and Pavia, Italy)

OP 22. *Effect of cyclodextrins on transthyretin amyloid formation*

H. Jono, T. Anno, Y. Misumi, Y. Mori, K. Motoyama, M. Ueda, Y. Horibata, M. Shono, K. Obayashi, H. Arima, Y. Ando  
(Kumamoto, Japan)

OP 23. *Small molecules and macromolecules for the inhibition of  $\beta 2$  microglobulin fibrillogenesis*

S. Giorgetti, R. Porcari, S. Raimondi, J. Steyaert, K. Domanska, S. Vanderhaegen, A. Relini, C. Parrini, S. Gliozzi, M. Salmona, M. Bucciantini, M. Stefani, A. Gallanti, I. Zorzoli, G. Esposito, M. Stoppini, V. Bellotti  
(Pavia, Florence, Milan, Udine, Genoa, Italy and Brussels, Belgium)

OP 24. *Macrophage dependent elimination of amyloid following treatment with anti SAP antibody*

G.A. Tennent, A. Loesch, M. Kahan, K. Bodin, S. Ellmerich, S. Minogue, M.B. Pepys  
(London, UK)

8:50–9:05 Jeffery W. Kelly: *Targeted molecules perspective*

- OP 25. *ALN-TTR, an RNAi therapeutic for the treatment of transthyretin-mediated amyloidosis*  
 R. Alvarez, T. Borland, Q. Chen, S. Milstein, T. Nguyen, G. Hinkle, S. Kuchimanchi, J. Costigan, V. Ristoiu, G. Wang, G. Cole, R. Dorkin, A. Akinc, L. Nechev, V. Kosovrasti, L. Tchangov, M. Tracy, L. Jeffs, I. MacLachlan, P. Lutwyche, D. Martins, S. Costelha, M.J. Saraiva, D.W.Y. Sah  
 (Cambridge, MA, USA, Burnaby, BC, Canada and Porto, Portugal)
- OP 26. *Evaluation of ALN-TTR on transthyretin tissue deposition in a FAP V30M animal model*  
 S. Costelha, R. Alvarez, T. Borland, L. Nechev, L. Jeffs, D.W.Y. Sah, M.J. Saraiva  
 (Porto, Portugal, Cambridge, MA, USA, Burnaby, BC, Canada)
- OP 27. *siRNA therapy for TTR-related ocular amyloidosis*  
 M. Tasaki, H. Jono, M. Ueda, R. Hara, K. Obayashi, T. Kawaji, A. Rene, Y. Mori, T. Yamashita, Y. Ando  
 (Kumamoto, Japan and Cambridge, MA, USA)
- OP 28. *Antisense oligonucleotide therapy for TTR amyloidosis*  
 M.D. Benson, S. Pandey, D. Witchell, A. Jazayeri, A. Siwkowski, B. Monia, B. Kluge-Beckerman  
 (Indianapolis, IN, and Carlsbad, CA, USA)
- OP 29. *Preclinical siRNA therapeutics for AL amyloidosis*  
 B.M. Hovey, J.E. Ward, P. Soo Hoo, C. O'Hara, L.H. Connors, D.C. Seldin  
 (Boston, MA, USA)

10:05–10:20 Merrill D. Benson: *Gene therapy perspective*

**Tuesday, April 20**  
**10:20–10:40**

**Coffee break**

**Tuesday, April 20**  
**10:40–12:30**  
**Hall Fori Imperiali**

**Parallel session**

**Diagnosis – Proteomics in pathogenesis and diagnosis**

Chairmen: Giampaolo Merlini and Ahmet Dogan

10:40–10:55 Giampaolo Merlini: *State of the art*

- OP 30. *Proteome immunoglobulin light chain amyloidosis (AL): Insights into the pathogenesis*  
 A. Dogan, J.D. Theis, J.D. Gamez, D.L. Murray, R.S. Abraham, K.L. Grogg, J.A. Katzmann, A. Dispenzieri, S.R. Zeldenrust, M. Ramirez-Alvarado, J.A. Vrana  
 (Rochester, MN, USA)
- OP 31. *Proteome of serum amyloid A protein (SAA) associated amyloidosis (AA)*  
 A. Dogan, J.D. Theis, J.D. Gamez, K.L. Grogg, N. Leung, A. Dispenzieri, S.R. Zeldenrust, J.A. Vrana  
 (Rochester, MN, USA)
- OP 32. *Characterization of protein profiles from amyloid adipose tissue using shotgun proteomic approach*  
 P. Mauri, F. Brambilla, V. Valentini, D. Di Silvestre, A. De Palma, G. Merlini, F. Lavatelli  
 (Segrate, MI and Pavia, Italy)

- OP 33. *Diagnosis and classification of systemic amyloidosis in abdominal subcutaneous fat aspiration specimens using mass spectrometry based proteomics*  
 J.A. Vrana, J.D. Theis, J.D. Gamez, P.J. Kurtin, K. L. Grogg,  
 A. Dispenzieri, S.R. Zeldenrust, A. Dogan  
 (Rochester, MN, USA)
- OP 34. *Proteomic mass spectrometry analysis of nerve allows subtyping of amyloid neuropathies*  
 S.R. Zeldenrust, C.J. Klein, J.A. Vrana, P.J. Dyck, P. J. B. Dyck,  
 R.J. Spinner, M.L. Mauermann, R.B. Bergen, J.D. Theis, A. Dogan  
 (Rochester, MN, USA)
- OP 35. *Co-immunoprecipitation as a method for isolating and studying circulating monoclonal free light chains and their interacting proteins in serum*  
 F. Lavatelli, V. Valentini, P. Mauri, F. Brambilla, P. Rognoni,  
 G. Palladini, V. Perfetti, S. Casarini, G. Sarais, G. Merlini  
 (Pavia, and Segrate, MI, Italy)

12:15–12:30 Ahmet Dogan: *Perspectives*

**Tuesday, April 20**  
**10:55–12:50**  
**Hall Foro dei**  
**Cesari**

**Parallel session**

**Diagnosis – Imaging and histochemistry**

Chairmen: Christoph Röcken and Philip Hawkins

10:40–10:55 Christoph Röcken: *State of the art*

- OP 36. *Role of dual modality I123 serum amyloid P component SPECT-CT imaging in amyloidosis*  
 D.F. Hutt, T. Lane, J.D. Gillmore, H.J. Lachmann, S.D.J. Gibbs,  
 P.T. Sattianayagam, D. Gopaul, A.M. Quigley, P.N. Hawkins,  
 A.D. Wechalekar  
 (London, UK)
- OP 37. *The fibril-reactive antibody 11-1F4 co-localizes with amyloid in patients with AL amyloidosis*  
 J.S. Wall, S.J. Kennel, A. Stuckey, D.W. Townsend, K. Wells,  
 M.G. Stabin, A. Solomon  
 (Knoxville and Nashville, TN, USA)
- OP 38. *<sup>125</sup>I-labeled, heparin-reactive protamine as a novel amyloid imaging reagent*  
 J.S. Wall, T. Richey, A. Stuckey, R. Donnell, E. Martin, A. Solomon,  
 S.J. Kennel  
 (Knoxville, TN, USA)
- OP 39. *Biodistribution of <sup>125</sup>I-labeled heparan sulphate-reactive scFv in AA amyloidotic mice*  
 J.S. Wall, T. Richey, A. Stuckey, A. Oosterhof, T. van Kuppevelt,  
 R. Donnell, A. Solomon, S.J. Kennel  
 (Knoxville, TN, USA and Nijmegen, The Netherlands)
- OP 40. *Classification of 14 different amyloid types using validated antibodies on tissue sections*  
 R.P. Linke  
 (Martinsried, Germany)
- OP 41. *Diagnostic performance of immuno-electron microscopy of abdominal fat in systemic amyloidoses*  
 G. Palladini, L. Verga, S. Corona, L. Obici, P. Morbini, F. Lavatelli,  
 S. Donadei, G. Sarais, L. Roggeri, A. Foli, P. Russo, L. Zenone Bragotti,  
 M. Paulli, L. Minoli, U. Magrini, G. Merlini  
 (Pavia, Italy)

OP 42. *Diagnostic performance of measuring free light chains in fat tissue of patients with AL amyloidosis*

J. Bijzet, I.I. van Gameren, P.C. Limburg, R. Bos, E. Vellenga,  
B.P.C. Hazenberg  
(Groningen, The Netherlands)

12:20–12:35 Philip Hawkins: *Perspectives*

**Tuesday, April 20**  
**13:00–14:30**

**Lunch and poster viewing**

**Tuesday, April 20**  
**14:30–16:35**  
**Hall Fori Imperiali**

**Parallel session**

**Biology, clinical presentation and prognosis in AL amyloidosis**

Chairmen: Meletios Dimopoulos and Alan Solomon

14:30–14:45 Meletios Dimopoulos: *State of the art*

OP 43. *Adaptive autophagy in normal and neoplastic plasma cells*

N. Pengo, L. Oliva, G. Palladini, A. Merlini, F. Fontana, E. Pasqualetto,  
R. Sitia, S. Cenci  
(Milan and Pavia, Italy)

OP 44. *Pathobiologic associations of plasma cell (PC) overexpression of Cyclin D1 (CCND1) in systemic AL amyloidosis (AL)*

R.L. Comenzo, J.E. Hoffman, H. Hassoun, H. Landau, L. Iyer, P. Zhou  
(Boston, MA, Weston, FL and New York, NY, USA)

OP 45. *Oligomeric amyloidogenic light chains are found in urinary exosomes of patients with AL amyloidosis*

M. Ramirez-Alvarado, C.J. Ward, B.Q. Huang, X. Gong, M.C. Hogan,  
B.J. Madden, C. Charlesworth, N. Leung  
(Rochester, MN, USA)

OP 46. *Contribution of light chain variable region genes to organ tropism and survival in AL amyloidosis*

T. Prokaeva, B. Spencer, G. Doros, L.H. Connors, M. Skinner,  
D.C. Seldin  
(Boston, MA, USA)

OP 47. *A model using cardiac troponin T, albumin and uric acid accurately predicts treatment related mortality in patients with amyloidosis undergoing autologous stem cell transplantation*

N. Leung, S. Kumar, A. Dispenzieri, M.Q. Lacy, F. Buadi,  
S.R. Hayman, D. Dingli, W.J. Hogan, M.A. Gertz  
(Rochester, MN, USA)

OP 48. *Clinical outcome of systemic AL amyloidosis affecting the kidneys*

J.H. Pinney, H.J. Lachmann, L. Bansil, A.D. Wechalekar,  
J.A. Gilbertson, D.M. Rowczenio, P.T. Sattianayagam, S.D.J. Gibbs,  
E. Orlandi, N.L. Wassef, A.R. Bradwell, P.N. Hawkins, J.D. Gillmore  
(London and Birmingham, UK)

OP 49. *Liver involvement as the hallmark of aggressive disease in AL amyloidosis: distinctive clinical features and prognosis in 225 patients*

G. Palladini, P. Russo, A. Foli, L. Zenone Bragotti, V. Perfetti, L. Obici,  
F. Lavatelli, M. Nuvolone, G. Merlini  
(Pavia, Italy)

OP 50. *Clinical characteristics and treatment outcome of amyloid and IgM related peripheral neuropathy in Waldenström's macroglobulinemia*

S.P. Treon, C. Hanzis, L. Ioakimidis, C. Patterson, Z.R. Hunter,  
P.S. Sheehy, R.J. Manning  
(Boston, MA, USA)

16:20–16:35 Alan Solomon: *Perspectives*

**Tuesday, April 20**  
**14:30–16:25**  
**Hall Foro dei**  
**Cesari**

**Parallel session**  
**Clinical presentation and prognosis in ATTR and senile systemic amyloidosis**

Chairmen: Shu-ichi Ikeda and Rodney Falk

14:30–14:45 Shu-ichi Ikeda: *State of the art*

OP 51. *A possible role for miRNA silencing in disease penetrance and phenotype variation in Swedish TTR Val30Met carriers*

N. Norgren, M. Olsson, K. Obayashi, V. Plante-Bordeneuve, O.B. Suhr, K. Cederquist, J. Jonasson  
(Umeå, Sweden, Kumamoto, Japan and Créteil, France)

OP 52. *NT-proBNP is a novel and powerful prognostic marker for transthyretin amyloidosis*

L. Obici, G. Palladini, S. Perlini, F. Musca, F. Salinaro, P. Russo, A. Foli, S. Donadei, M. Pasotti, G. Sarais, V. Perfetti, R. Albertini, G. Merlini  
(Pavia, Italy)

OP 53. *Phenotype and natural history of transthyretin alanine 60 (T60A) amyloidosis*

P.T. Sattianayagam, A. Hahn, S.D.J. Gibbs, C.J. Whelan, D.M. Rowczenio, H. Trojer, T.L. Russell, J.H. Pinney, H.J. Lachmann, A.D. Wechalekar, P.N. Hawkins, J.A. Gilbertson, T. Hunt, J.D. Gillmore  
(London, UK)

OP 54. *Initial findings from the Transthyretin Amyloidosis Outcomes Survey (THAOS) – A global web-based registry*

V. Plante-Bordeneuve, T. Coelho, B.G. Ericzon, R.H. Falk, S. Ikeda, M. Maurer, O.B. Suhr, P. Trigo, D.R. Grogan  
(Créteil, France, Porto, Portugal, Stockholm, Sweden, Boston, MA, USA, Matsumoto, Japan, New York, NY, USA, Umeå, Sweden, Buenos Aires, Argentina and Cambridge, MA, USA)

OP 55. *Hereditary transthyretin amyloidosis with exclusive cardiac phenotype: a multicenter Italian study*

C.C. Quarta, L. Obici, C. Rapezzi, S. Perlini, S. Longhi, G. Palladini, A. Ferlini, F. Salvi, C. Villani, C. Gagliardi, G. Merlini  
(Bologna, Pavia and Ferrara, Italy)

OP 56. *Clinical features and survival in senile systemic amyloidosis: comparison to familial transthyretin cardiomyopathy*

L.H. Connors, G. Doros, F. Sam, D.C. Seldin, M. Skinner  
(Boston, MA, USA)

OP 57. *Epidemiology of conduction disorders in familial amyloid polyneuropathy*

V. Algalarrondo, S. Dinanian, C. Juin, D. Samuel, D. Adams, M.S. Slama  
(Clamart, France)

16:10–16:25 Rodney Falk: *Perspectives*

**Tuesday, April 20**  
**14:30–16:35**  
**Hall Aurelia**

**Parallel session**  
**Clinical presentation and prognosis in AA and other types of amyloidosis**

Chairpersons: Martha Skinner and Avi Livneh

14:30–14:45 Martha Skinner: *State of the art*

**Tuesday, April 20**  
**14:30–16:35**  
**Hall Aurelia**

- OP 58. *Clinical and pathological phenotype of leukocyte cell-derived chemotaxin-2 (LECT2) amyloidosis (ALECT2)*  
A. Dogan, J.D. Theis, J.A. Vrana, V.H. Jimenez-Zepeda, M.Q. Lacy, N. Leung, A. Dispenzieri, S.R. Zeldenrust, R. Fonseca, J.A. Gilbertson, T. Hunt, A.D. Wechalekar, H.J. Lachmann, D. Rowczenio, P.N. Hawkins, J.D. Gillmore  
(Rochester, MN, USA and London, UK)
- OP 59. *Long-term follow-up of patients with hereditary fibrinogen A $\alpha$ -chain amyloidosis*  
I. Tavares, J. Santos, L. Moreira, P. Lacerda, J. Pinheiro, P. Costa, L. Lobato  
(Porto, Portugal)
- OP 60. *LEU75PRO APOA-I amyloidosis in the province of Brescia (northern Italy). Report of the registry*  
A. Negrinelli, G. Gregorini, F. Scolari, P. Gaggia, N. Dallera, L. Biasi, M.L. Muiesan, M. Nardi, T. Scalvini, S. Donadei, M. Pasotti, L. Obici, G. Merlini  
(Brescia and Pavia, Italy)
- OP 61. *Galectin 7-associated cutaneous amyloidosis*  
P. Westermark, C. Murphy, M. Eulitz, C. Wallgren-Pettersson, B. Udd, U. Hellman, E. Ihse, D. Weiss, A. Solomon  
(Uppsala, Sweden, Knoxville, TN, USA and Helsinki, Finland)
- OP 62. *Leukocyte Chemotactic Factor 2 (LECT2)-associated renal amyloidosis*  
C.L. Murphy, S. Wang, D. Kestler, C. Larsen, D. Benson, D.T. Weiss, A. Solomon  
(Knoxville, TN, Little Rock, AK and Columbus OH, USA)
- OP 63. *The changing face of AA amyloidosis: a single center experience*  
S. Girnius, L. Dember, G. Doros, M. Skinner  
(Boston, MA, USA)
- OP 64. *Natural history of hereditary lysozyme amyloidosis*  
P.T. Sattianayagam, D.M. Rowczenio, S.D.J. Gibbs, H. Trojer, T.L. Russell, J.H. Pinney, H.J. Lachmann, A.D. Wechalekar, P.N. Hawkins, M.B. Pepys, J.A. Gilbertson, T. Hunt, J.D. Gillmore  
(London, UK)
- OP 65. *Survival on dialysis and outcome after renal transplantation in AA amyloidosis*  
H.J. Lachmann, J.D. Gillmore, A.D. Wechalekar, P.T. Sattianayagam, S.D.J. Gibbs, J.H. Pinney, H.J.B. Goodman, M. Offer, J.R. Gallimore, J.A. Gilbertson, T. Hunt, D. Gopaul, D.F. Hutt, P.N. Hawkins  
(London, UK)

16:20–16:35 Avi Livneh: *Perspectives*

**Tuesday, April 20**  
**16:30–17:30**

**Poster viewing (refreshments available during poster viewing)**

*Poster Award Committee: Bouke Hazenberg (Coordinator), David Adams, Lawreen Connors, Julian Gillmore, Helen Lachmann, Laura Obici, Stefano Perlini*

**Poster Group 8**

- PP 81. *A new transthyretin mutation associated with leptomeningeal amyloidosis*  
J.J. Liepnieks, D.W. Dickson, M.D. Benson  
(Indianapolis, IN, USA and Jacksonville, FL, USA)
- PP 82. *Transthyretin-derived amyloid deposition in ligaments and tendons of various organ sites*  
T. Sueyoshi, M. Ueda, H. Jono, Y. Horibata, M. Shono, K. Obayashi, A. Sei, H. Mizuta, Y. Ando  
(Kumamoto, Japan)



**Tuesday, April 20**  
**16:30–17:30**

- PP 83. *Novel therapy for transthyretin-related ocular amyloidosis*  
R. Hara, T. Kawaji, H. Tanihara, Y. Ando  
(Kumamoto, Japan)
- PP 84. *Effect of liver transplantation on the survival of patients with ordinary onset FAP in Japan*  
T. Yamashita, Y. Ando, S. Okamoto, M. Yohei, T. Hitahara, M. Ueda, K. Obayashi, M. Nakamura, H. Jono, K. Asonuma, Y. Inomata, M. Uchino  
(Kumamoto, Japan)
- PP 85. *Experience of ATTR in a single centre: findings among 220 patients*  
D.M. Rowczenio, H.J. Lachmann, S.D.J. Gibbs, J.A. Gilbertson, T. Hunt, T.L. Russell, P.T. Sattianayagam, H. Trojer, A.D. Wechalekar, C.J. Whelan, P.N. Hawkins, J.D. Gillmore  
(London, UK)
- PP 86. *Hemodynamic responses after tilt reversal in FAP*  
K. Obayashi, R. Hörnsten, U. Wiklund, M. Karlsson, S. Okamoto, Y. Ando, O.B. Suhr  
(Umeå, Sweden and Kumamoto, Japan)
- PP 87. *Liver transplantation promoted amyloid turnover in FAP*  
K. Obayashi, M. Ueda, Y. Misumi, T. Yamashita, H. Jono, M. Tasaki, M. Shono, M. Yazaki, F. Kametani, Y. Ohya, K. Asonuma, Y. Inomata, S. Ikeda, Y. Ando  
(Kumamoto, Matsumoto and Tokyo, Japan)
- PP 88. *A homozygote case of FAP ATTR Val30Met in a non-endemic area*  
Y. Kumabe, A. Miura, T. Yamashita, T. Oshima, Y. Misumi, M. Ueda, K. Obayashi, Y. Horibata, H. Jono, Y. Ando, M. Uchino  
(Kumamoto, Japan)
- PP 89. *A prospective evaluation of the morbidity and mortality of transthyretin amyloid cardiomyopathy (ATTR-CM): The Transthyretin Amyloidosis Cardiac Study (TRACS)*  
F.L. Ruberg, M. Maurer, D.P. Judge, S. Zeldenrust, M. Skinner, A.Y. Kim, R.H. Falk, K. Cheung, J. Packman, D.R. Grogan  
(Boston, MA, Cambridge, MA and Rochester, MN, USA)
- PP 90. *Prognostic value of cardiomyopathy in Swedish liver transplanted patients for familial amyloidotic polyneuropathy*  
S. Okamoto, J. Wixner, B.G. Ericzon, S. Friman, P. Lindqvist, M. Henein, O.B. Suhr  
(Umeå, Huddinge and Göteborg, Sweden)
- PP 91. *Hereditary amyloidosis by transthyretin: diagnosis of heterozygous mutation Val30Met in two brothers*  
G. Giglio, G. Antuzzi, F. Carrozza, L. Obici, M. Musacchio  
(Campobasso and Pavia, Italy)

#### **Poster Group 9**

- PP 92. *Combined liver–kidney transplantation in FAP TTR V30M: Nephrological assesment*  
L. Lobato, I. Beirão, R. Seca, H. Pessegueiro, M.J. Rocha, J. Queiroz, M. Gomes, A. Castro Henriques, M. Teixeira, R. Almeida  
(Porto, Portugal)
- PP 93. *The outcome after liver transplantation in ATTR non Met30 familial amyloid polyneuropathy – the French experience*  
N. Sanda, V. Algalarrondo, T. Antonini, P. Lozeron, L.L. Mariani, C. Lacroix, H. Husson, S. Dinanian, P. Azulay, D. Castaing, M. Slama, D. Samuel, D. Adams  
(Paris, France)

**Tuesday, April 20**  
**16:30–17:30**

- PP 94. *De novo amyloid polyneuropathy in FAP domino liver recipients : the French experience*  
D. Adams, C. Lacroix, T. Antonini, P. Lozeron, C. Denier,  
S. Epelbaum, F. Blandin, V. Karam, D. Azoulay, R. Adam, D. Castaing,  
D. Samuel  
(Paris, France)
- PP 95. *Frequency of arrhythmia in Swedish familial amyloidotic polyneuropathy (ATTR Val30Met) transplanted*  
S. Okamoto, R. Hörnsten, O.B. Suhr  
(Umeå, Sweden and Kumamoto, Japan)
- PP 96. *Gastric emptying in familial amyloidotic neuropathy: impact of autonomic neuropathy*  
J. Wixner, U. Wiklund, A. Rydh, R. Hörnsten, O.B. Suhr  
(Umeå, Sweden)
- PP 97. *The interstitial cells of Cajal but not the enteric nerves are depleted in the gastric wall of patients with familial amyloid polyneuropathy*  
I. Anan, J. Wixner, K. Obayashi, Y. Ando, O.B. Suhr  
(Umeå, Sweden and Kumamoto, Japan)
- PP 98. *Relationship between objective measures of neuropathy and quality of life in stages of severity of transthyretin familial amyloid polyneuropathy*  
T. Coelho, I. Merckies, A. Vinik, E.J. Vinik, J. Chan, J. Packman,  
D.R. Grogan  
(Porto, Portugal, Hoofddorp, and Maastrich,  
The Netherlands, Norfolk, VA, and Cambridge, MA, USA)
- PP 99. *High incidence of paroxysmic AV block and prophylactic pacing in familial amyloid polyneuropathy*  
S. Dinanian, C. Juin, S.L. Bennani, C. Sebag, D. Adams, M.S. Slama  
(Clamart, France)
- PP 100. *Does genetic variation in TTR identified in the general population predict attenuated phenotypes?*  
L.S. Hornstrup, R. Frikke-Schmidt, C.L. Haase, A. Tybjærg Hansen  
(Copenhagen, Denmark)
- PP 101. *Clinical phenotype and course of transthyretin Val107 and late onset Met30 familial amyloid polyneuropathy*  
L.L. Mariani, P. Lozeron, C. Lacroix, M. Misrahi, D. Adams  
(Le Kremlin-Bicêtre, France)
- PP 102. *Elastorrhexia, macroglossia and enlarging salivary glands: 3 new clinical features of the Y78F transthyretin mutation*  
N. Magy-Bertrand, M.D. Benson, N. Meaux-Ruault, S. Valleix, H. Gil  
(Besancon, France, Indianapolis, IN, USA and Paris, France)

**Poster group 10**

- PP 103. *<sup>99m</sup>Tc-labeled serum amyloid P component as a tool for evaluating novel amyloid imaging agents*  
J.S. Wall, T. Richey, P.N. Hawkins, A. Solomon, S.J. Kennel  
(Knoxville, TN, USA and London, UK)
- PP 104. *ALchemy – a nationwide study of chemotherapy for systemic AL amyloidosis in the UK*  
T. Lane, D.M. Foard, A.D. Wechalekar, S.D.J. Gibbs, H.J. Lachmann,  
P.T. Sattianayagam, J.H. Pinney, L.G. Rannigan, J.D. Gillmore,  
P.N. Hawkins  
(London, UK)
- PP 105. *Knowledge management for clinical decision support in amyloidosis*  
S. Rubrichi, M. Stefanelli, S. Quaglini, P. Russo, G. Palladini,  
F. Lavatelli, G. Merlini  
(Pavia, Italy)

**Tuesday, April 20**  
**16:30–17:30**

- PP 106. *Change in amount of amyloid in fat and bone marrow after treatment of AL amyloidosis with HDM/SCT*  
C.A. Libbey, L.H. Connors, A. Badiee, C. O'Hara, M. Skinner  
(Boston, MA, USA)
- PP 107. *AMOnto: an ontology-based service for the AMICA project*  
G. Leonardi, M. Stefanelli, S. Panzarasa, S. Rubrichi, P. Russo,  
G. Palladini, F. Lavatelli, G. Merlini  
(Pavia, Italy)
- PP 108. *A workflow management system for the biological samples exchange within the amyloidosis network*  
S. Panzarasa, S. Quaglini, R. Ferrari, M. Stefanelli, A. Foli, G. Palladini,  
P. Russo, F. Lavatelli, G. Merlini  
(Pavia, Italy)
- PP 109. *Measurable regression of systemic AL amyloid in fat tissue after response of serum free light chain*  
I.I. Van Gameren, J. Bijzet, R. Bos, P.C. Limburg, E. Vellenga,  
B.P.C. Hazenberg  
(Groningen, The Netherlands)
- PP 110. *How can I understand?*  
P. Neely  
(Brisbane, Australia)
- PP 111. *Biochemical characterization of nerve amyloid in hereditary transthyretin amyloidosis patients with and without liver transplant*  
J.J. Liepnieks, L.Q. Zhang, M.D. Benson  
(Indianapolis, IN, USA)
- PP 112. *Current practice in amyloid detection and typing among renal pathologists*  
M.M. Picken  
(Chicago, IL, USA)
- PP 113. *Identification of 4 chemically different amyloid types in 24 patients via routine endomyocardial biopsies and validated immunohistochemistry*  
D. Lassner, U.M. Gross, R.P. Linke, F. Escher, H.P. Schultheiss,  
U. Kühl  
(Berlin and Martinsried, Germany)
- PP 114. *Diagnostic performance of transthyretin measurement in fat tissue of patients with ATTR amyloidosis*  
B.P.C. Hazenberg, B. van Schijndel, J. Bijzet, P.C. Limburg, R. Bos,  
E.B. Haagsma  
(Groningen, The Netherlands)
- PP 115. *20 years' experience of subcutaneous fat tissue aspirates: Benefits and limits*  
F. Bergesio, G. Curciarello, S. Di Lollo, F. Manescalchi, S. Nigrelli,  
S. Farsetti, L. Caroti, S. Audino, F. Perfetto  
(Florence, Italy)
- PP 116. *Patterns of myocardial infiltration in cardiac amyloidosis: A morphometric histologic study*  
S. Longhi, O. Leone, C.C. Quarta, C. Villani, C. Gagliardi, G. Galati,  
C. Rapezzi  
(Bologna, Italy)
- PP 117. *Role of minor salivary gland biopsy in the diagnosis of systemic amyloidosis: Results of a prospective study in 62 patients*  
A. Foli, G. Palladini, R. Caporali, L. Verga, P. Morbini, L. Obici,  
P. Russo, G. Sarais, S. Donadei, C. Montecucco, G. Merlini  
(Pavia, Italy)

**Tuesday, April 20**  
**16:30–17:30**

**Poster Group 11**

- PP 118. *Solid organ transplantation in AL amyloidosis*  
P.T. Sattianayagam, S.D.J. Gibbs, A.D. Wechalekar, H.J. Lachmann, C.J. Whelan, J.H. Pinney, P.N. Hawkins, J.D. Gillmore  
(London, UK)
- PP 119. *Decline in the incidence of renal failure due to amyloidosis associated with inflammatory rheumatic diseases*  
K. Immonen, T. Pettersson, P. Finne, C. Grönhagen-Riska, T. Klaukka, H. Kautiainen, M. Hakala  
(Helsinki and Tampere, Finland)
- PP 120. *Regression of cardiac wall thickness following chemotherapy and stem-cell transplantation for AL amyloidosis*  
H.K. Meier-Ewert, V. Sancharawala, J. Berk, K.T. Finn, M. Skinner, D.C. Seldin, F.L. Ruberg  
(Boston, MA, USA)
- PP 121. *Survival and prognostic factors amongst Australian patients with AL amyloidosis*  
P. Mollee, J. Tate, K. Morris, J. Wellwood, M. Browne, P. Marlton, R. Bird, A.K. Mills, P. Wood, S. Mapp, D. Gill  
(Brisbane and Coffs Harbour, Australia)
- PP 122. *Systemic AL amyloidosis with renal involvement in a region of Western France*  
E. Moumas, E. Desport, C. Lacombe, J.M. Gombert, J.M. Goujon, F. Bridoux, G. Touchard  
(Poitiers, France)
- PP 123. *Double autologous bone marrow transplantation (ASCT) and orthotopic liver transplantation (OLT) in a patient with primary AL amyloidosis*  
G. Binotto, A. Pavan, L. Trentin, P. Boccagni, M. Zaninotto, G. Semenzato, F. Adami  
(Padova, Italy)
- PP 124. *Vesicular senile systemic amyloidosis*  
C. Murphy, S. Wang, D. Kestler, F. Klein, A. Stewart, D. Weiss, A. Solomon  
(Knoxville, TN, USA)

**Poster Group 12**

- PP 125. *Is it of value to restore sinus rhythm in cardiac amyloidosis?*  
R.H. Falk, J.L. Kruger, G.F. Michaud, U. Tedrow, R.M. John  
(Boston, MA, USA)
- PP 126. *Safety and value of endomyocardial biopsy in cardiac amyloidosis*  
R.H. Falk, J.L. Kruger, G.L. Winters, R.N. Mitchell, R.F. Padera  
(Boston, MA, USA)
- PP 127. *Predictors of survival for more than one year in primary cardiac amyloidosis*  
H. Suradi, K. Hamidi Asl, M.K. Das, M.D. Benson  
(Indianapolis, IN, USA)
- PP 128. *High sensitivity troponin assay (hsTnT): utility in patients with AL*  
A. Dispenzieri, M.A. Gertz, A.K. Saenger, S.K. Kumar, M.Q. Lacy, R.A. Kyle, N. Leung, S.R. Zeldenrust, S.R. Hayman, F. Buadi, P.R. Greipp, S.V. Rajkumar, S.R. Russell, K. Detweiler-Short, D. Dingli, J.A. Lust, A.S. Jaffe  
(Rochester, MN, USA)
- PP 129. *Can estimates of heart rate variability secondary to fluctuations in autonomic nerve activity be used for detection of peripheral small fiber neuropathy in Val30Met TTR amyloidosis?*  
V. Heldestad, R. Hörnsten, U. Wiklund, O.B. Suhr, E. Nordh  
(Umeå, Sweden)

**Tuesday, April 20**  
**16:30–17:30**

- PP 130. *Interference of cardiac amyloidosis on atrio-ventricular and intraventricular electrical conduction*  
F. Salinaro, I. Zunino, E. Demichele, I. Fracchioni, G. Palladini, C.C. Quarta, S. Longhi, F. Musca, L. Obici, P. Russo, A. Foli, V. Perfetti, C. Rapezzi, G. Merlini, S. Perlini  
(Pavia and Bologna, Italy)
- PP 131. *The contribution of the EKG / echocardiographic mass ratio to the diagnosis of cardiac AL amyloidosis*  
F. Salinaro, I. Fracchioni, G. Palladini, C.C. Quarta, S. Longhi, F. Musca, I. Zunino, E. Demichele, A. Milan, F. Veglio, L. Obici, V. Perfetti, C. Rapezzi, G. Merlini, S. Perlini  
(Pavia, Bologna, and Turin, Italy)
- PP 132. *Functional correlates of increased NT-proBNP and troponin I in cardiac AL amyloidosis*  
F. Musca, F. Salinaro, I. Fracchioni, G. Palladini, L. Obici, R. Albertini, R. Moratti, G. Palladini, C. Rapezzi, G. Merlini, S. Perlini  
(Pavia and Bologna, Italy)
- PP 133. *Rotational mechanics of the left ventricle in AL amyloidosis*  
F. Cappelli, M.C. Porciani, F. Perfetto, F. De Antonis, G. Castelli, M. Ciaccheri, G. Filice, L. Padeletti, F. Bergesio  
(Florence, Italy)
- PP 134. *Tissue Doppler and strain imaging: a new tool for early detection of cardiac amyloidosis*  
F. De Antonis, M.C. Porciani, F. Perfetto, F. Cappelli, G. Castelli, M. Ciaccheri, G. Palladini, L. Padeletti, F. Bergesio  
(Florence, Italy)
- PP 135. *Hoher monitoring in AL amyloidosis: prognostic relevance in the era of cardiac biomarkers*  
G. Palladini, S. Perlini, P. Russo, F. Salinaro, A. Foli, R. Albertini, L. Zenone Bragotti, F. Lavatelli, M. Nuvolone, L. Obici, R. Moratti, G. Merlini  
(Pavia, Italy)
- PP 136. *N-terminal pro natriuretic peptide type B (NT-proBNP) is a reliable marker of cardiac response in patients with AL amyloidosis and renal failure*  
G. Palladini, P.N. Hawkins, A. Foli, H.J. Lachmann, S. Perlini, J.D. Gillmore, G. Merlini, A.D. Wechalekar  
(Pavia, Italy and London, UK)
- PP 137. *High-sensitivity cardiac troponin is the most powerful prognostic determinant and predicts progression of cardiac dysfunction in AL amyloidosis*  
G. Palladini, A. Barassi, G. Sarais, R. Capra, P. Milani, R. Albertini, S. Perlini, A. Foli, P. Russo, L. Zenone Bragotti, L. Obici, R. Moratti, G.V. Melzi D'Eril, G. Merlini  
(Pavia and Milan, Italy)
- PP 138. *<sup>99m</sup>TcDPD scintigraphy detects transthyretin cardiac amyloidosis across a wide spectrum of involvement*  
C.C. Quarta, P.L. Guidalotti, S. Longhi, P. Ciliberti, O. Leone, G. Galati, A. Ferlini, E. Biagini, C. Villani, C. Gagliardi, C. Pettinato, C. Rapezzi  
(Bologna and Ferrara, Italy)

**Poster Group 13**

- PP 139. *A novel mechanism of diversification and structural modification of amyloid light chains: evidence of a large nucleotide deletion in the framework 1 of a lambdaI variable region*  
V. Perfetti, S. Casarini, P. Rognoni, F. Lavatelli, G. Palladini, L. Obici, G. Merlini  
(Pavia, Italy)

**Tuesday, April 20**  
**16:30–17:30**

- PP 140. *In vivo* visualization of amyloid deposits in the heart using [<sup>11</sup>C]PIB and positron emission tomography (PET)  
G. Antoni, J. Sörensen, G. Wikström, J. Axelsson, K. Carlson, O. Vedin, B. Långström, P. Westermark  
(Uppsala, Sweden)
- PP 141. *Prevalence of senile systemic amyloidosis in patients with idiopathic carpal tunnel syndrome*  
Y. Sekijima, S. Uchiyama, K. Tojo, K. Sano, T. Imaeda, H. Kato, S. Ikeda  
(Matsumoto, Japan)
- PP 142. *Clinicopathologic findings in Japanese patients with senile systemic amyloidosis (SSA) – first report elucidating the prevalence of SSA in an Asian country*  
Y. Su, Y. Horibata, M. Ueda, M. Tasaki, Y. Misumi, J. Guo, M. Shono, H. Jono, K. Obayashi, H. Ogawa, Y. Ando  
(Kumamoto, Japan)
- PP 143. *Left ventricular dyssynchrony contributes to the reduced heart rate variability in familial amyloidosis*  
R. Hörnsten, Z. Ying, P. Lindqvist, U. Wiklund, O.B. Suhr, M.Y. Henein  
(Umeå, Sweden)
- PP 144. *Echocardiographic evaluation of left and right ventricular functions in familial amyloidosis polyneuropathy*  
S.L. Bennani, V. Algalarrondo, S. Dinanian, J. Guiader, D. Adams, M.S. Slama  
(Clamart, France)
- PP 145. *Echocardiography and right heart catheterization for the diagnosis of restrictive cardiopathy in FAP*  
S.L. Bennani, V. Algalarrondo, S. Dinanian, C. Juin, J. Guiader, D. Adams, M.S. Slama  
(Clamart, France)
- PP 146. *MRI assessment of cardiac involvement in patients with amyloidosis*  
P. Di Renzi, M. Di Girolamo, G. Della Longa, A. Coniglio, S. Bianchi  
(Rome, Italy)
- PP 147. *Assessment of left ventricular wall thickness in cardiac amyloidosis by different imaging modalities*  
C.J. Whelan, B. Pawarova, M. De Cruz, H.J. Lachmann, P.T. Sattianayagam, S.D.J. Gibbs, J.H. Pinney, J.D. Gillmore, P.N. Hawkins, A.D. Wechalekar  
(London, UK)
- PP 148. *Changes in serum NT-proBNP correlate with changes in both systolic and diastolic function in AL amyloidosis*  
C.J. Whelan, B. Pawarova, M. De Cruz, H.J. Lachmann, P.T. Sattianayagam, S.D.J. Gibbs, J.H. Pinney, J.D. Gillmore, N. Wassef, P.N. Hawkins, A.D. Wechalekar  
(London, UK)
- PP 149. *Outcomes of implantable defibrillators in patients with cardiac amyloidosis*  
G. Lin, A. Dispenzieri, M. Grogan, R. Kyle, P.A. Brady  
(Rochester, MN, USA)
- PP 150. *Does the presence or severity of late gadolinium enhancement by cardiac MRI predict outcomes in cardiac amyloidosis?*  
G. Lin, J. Glockner, A. Dispenzieri, P.A. Brady  
(Rochester, MN, USA)
- PP 151. *Troponin as a prognostic marker in cardiac amyloidosis*  
T. Apridonidze, R. Steingart, R. Comenzo, J. Hoffman, Y. Goldsmith, J. Bella, J. Liu  
(New York, NY, Boston, MA, Weston, FL, and Houston, TX, USA)

**Tuesday, April 20**  
**17:30–19:30**  
**Hall Fori Imperiali**

**Consensus Panels discussion**

17:30–18:10

**Assessment of organ involvement and response to therapy in ATTR amyloidosis**

Chairmen: Yukio Ando and John Berk

*Assessment of organ involvement and response to therapy in familial transthyretin amyloidosis: consensus guidelines*

J.L. Berk, O.B. Suhr, M.D. Benson, S. Perlini, S.I. Ikeda, L.H. Connors, P.J. Dyck, P. Westermark, T. Coelho, L.M. Dember, Y. Ando (Boston, MA, USA, Umeå, Sweden, Indianapolis, IN, USA, Pavia, Italy, Matsumoto, Japan, Rochester, MN, USA, Uppsala, Sweden, Santo Antonio, Portugal and Kumamoto, Japan)

18:10–18:50

**Indications and timing of organ transplantation in ATTR amyloidosis**

Chairmen: Ole Suhr and Steven Zeldenrust

*ATTR transplantation consensus panel 2009*

S.R. Zeldenrust, M. Skinner, M. Benson, Y. Ando, A. Stangou, M. Waddington-Cruz, T. Coelho, L. Obici, B.G. Ericzon, D. Samuel, A.D. Pinna, S.I. Ikeda, O.B. Suhr (Rochester, MN, USA, Boston, MA, USA, Indianapolis, IN, USA, Kumamoto, Japan, London, UK, Rio de Janeiro, Brazil, Porto, Portugal, Pavia, Italy, Huddinge, Sweden, Villejuif, France, Bologna, Italy, Matsumoto, Japan and Umeå, Sweden)

18:50–19:30

**Indications and timing of organ transplantation in non-ATTR amyloidosis**

Chairpersons: Laura Dember and Philip Hawkins

*Solid organ transplantation for non-TTR amyloidoses: consensus opinion*

L.M. Dember, J.D. Gillmore, W.D. Lewis, S. Pasquali, S.O. Schoenland, M.J. Semigran, P.N. Hawkins (Boston, Burlington, MA, USA, London, UK, Reggio Emilia, Italy and Heidelberg, Germany)

**Tuesday, April 20**  
**20:30**

Social dinner at Villa Miani

**Wednesday, April 21**

**Wednesday,**  
**April 21**  
**8:00–9:45**  
**Hall Fori Imperiali**

**Plenary Session**

**Therapy of ATTR amyloidosis**

Chairmen: John Berk and Yukio Ando

8:00–8:15 John Berk: *State of the art*

OP 66. *Tafamidis (Fx-1006A): a first-in-class disease-modifying therapy for transthyretin familial amyloid*

T. Coelho, L. Maia, A. Martins da Silva, M. Waddington-Cruz, V. Planté-Bordeneuve, P. Lozeron, O.B. Suhr, J. Campistol, I. Conceição, H. Schmidt, P. Trigo, J. Packman, D.R. Grogan (Porto, Portugal, Rio de Janeiro, Brasil, Créteil, France, Umeå, Sweden, Barcelona, Spain, Lisbon, Portugal, Münster, Germany, Buenos Aires, Argentina, and Cambridge, MA, USA)

- OP 67. *Efficacy and safety of long-term administration of diflunisal to familial amyloid polyneuropathy*  
K. Tojo, Y. Sekijima, H. Morita, J. Koyama, M. Kodaira, A. Tsuchiya-Suzuki, M. Yazaki, S.I. Ikeda  
(Matsumoto, Japan)
- OP 68. *Long-term data from the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR)*  
H.E. Wilczek, M. Larsson, B.G. Ericzon; on behalf of reporting members of the FAPWTR  
(Stockholm, Sweden)
- OP 69. *De novo familial amyloid polyneuropathy after domino liver transplantation*  
T.M. Antonini, D. Adams, V. Karam, F. Blandin, D. Azoulay, R. Adam, D. Castaing, D. Samuel  
(Villejuif and Le Kremlin-Bicêtre, France)
- OP 70. *The diflunisal trial: update on study drug tolerance and disease progression*  
J.L. Berk, P.J. Dyck, L. Obici, S.R. Zeldenrust, Y. Sekijima, T. Yamashita, Y. Ando, S.I. Ikeda, P. Gorevic, G. Merlini, J.W. Kelly, M. Skinner, A.B. Bisbee, O.B. Suhr, the Familial Amyloidosis Consortium  
(Boston, MA, Rochester, MN, USA, Pavia, Italy, Matsumoto, Japan, Kumamoto, Japan, New York, NY, La Jolla, CA, USA, and Umeå, Sweden)
- OP 71. *Liver transplantation for familial amyloid polyneuropathy: the King's College Hospital selection criteria*  
A.J. Stangou, M. Rela, M. Monaghan, J. Wendon, C.J. Mathias, J.G. O'Grady, N. Heaton  
(London, UK)

9:30–9:45 Yukio Ando: *Perspectives*

**Wednesday,  
April 21  
9:50–11:05  
Hall Fori Imperiali**

**Plenary Session  
High-dose chemotherapy in AL amyloidosis**  
Chairmen: David Seldin and Jean-Paul Fermand

9:50–10:05 David Seldin: *State of the art*

- OP 72. *Modified HDM/SCT in the treatment of AL amyloidosis: analysis of a Southwest Oncology Group trial*  
V. Santhorawala, V. Bolejack, J. Crowley, A. Hoering, K.T. Finn, S. Fennessey, D.C. Seldin, B. Barlogie  
(Boston, MA, USA, Seattle, WA, USA and Little Rock, AK, USA)
- OP 73. *Autologous stem cell transplantation (ASCT) versus M-Dex in AL amyloidosis: long term follow-up*  
A. Jaccard, E. Desport, V. Leblond, P. Moreau, X. Leleu, L. Benboubker, B. Kolb, C. Recher, B. Pegourier, B. Arnulf, F. Bridoux, J.P. Fermand  
(Limoges, Poitiers, Paris, Nantes, Lille, Tours, Reims, Toulouse and Grenoble, France)
- OP 74. *Adjuvant bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic AL amyloidosis*  
H. Landau, H. Hassoun, C. Bello, E. Hoover, X. Jia, E.R. Riedel, S.D. Nimer, R.L. Comenzo  
(New York, NY and Boston, MA, USA)



OP 75. *Results of two consecutive phase II trials of patients with systemic AL amyloidosis treated with high-dose melphalan after induction and mobilization chemotherapy*

S.O. Schönland, T. Bochtler, J. Perz, M. Hansberg, A. Mangatter, A.D. Ho, H. Goldschmidt, U. Hegenbart  
(Heidelberg, Germany)

10:50–11:05 Jean-Paul Femand: *Perspectives*

**Wednesday,  
April 21  
11:05–11:20**

**Coffee break**

**Wednesday,  
April 21  
11:20–12:50  
Hall Foro dei  
Cesari**

**Parallel Session  
Conventional and novel agents in AL amyloidosis**  
Chairmen: Stefan Schönland and Ray Comenzo

11:20–11:35 Stefan Schönland: *State of the art*

OP 76. *Oral melphalan and dexamethasone for AL amyloidosis: efficacy, prognostic factors and response criteria*

G. Palladini, A. Foli, P. Milani, P. Russo, L. Zenone Bragotti, S. Perlini, F. Lavatelli, L. Obici, V. Perfetti, G. Merlini  
(Pavia, Italy)

OP 77. *Long term follow up of bortezomib with dexamethasone as initial treatment for AL amyloidosis*

M.A. Dimopoulos, M. Roussou, C. Pamboukas, M. Migkou, M. Gavriatopoulou, E. Terpos, E. Kastritis  
(Athens, Greece)

OP 78. *CTD versus Mel-Dex as upfront treatment in AL amyloidosis: a matched case-control study*

S.D.J. Gibbs, J.D. Gillmore, P.T. Sattianayagam, H.J. Lachmann, T. Lane, H.J.B. Goodman, M. Offer, C.J. Whelan, D.M. Rowczenio, D.F. Hutt, J.A. Gilbertson, P.N. Hawkins, A.D. Wechalekar  
(London, UK)

OP 79. *High rates of overall and complete hematologic response in a prospective phase 1/2 study of weekly and twice-weekly bortezomib in relapsed AL amyloidosis*

R.L. Comenzo, U. Hegenbart, V. Santhorawala, G. Merlini, G. Palladini, J. Bladé, J.P. Femand, H. Hassoun, L. Heffner, R.A. Vescio, K. Liu, C. Enny, D.L. Esseltine, H. van de Velde, A. Cakana, D.E. Reece (Boston, MA, USA, Heidelberg, Germany, Pavia, Italy, Barcelona, Spain, Paris, France, Cambridge, MA, USA, Los Angeles, CA, USA, Beerse, Belgium, and Toronto, ON, Canada, On behalf of the Velcade CAN 2007 Investigators)

OP 80. *Durable hematologic complete responses can be achieved with Lenalidomide in AL amyloidosis*

V. Santhorawala, K.T. Finn, S. Fennessey, A. Shelton, L.M. Dember, J.B. Zeldis, M. Skinner, D.C. Seldin  
(Boston, MA, USA)

12:35–12:50 Ray Comenzo: *Perspectives*

**Wednesday,  
April 21  
11:20–13:00  
Hall Fori Imperiali**

**Parallel Session  
Novel agents and paradigms in AL amyloidosis**  
Chairpersons: Angela Dispenzieri and Steve Treon

11:20–11:35 Angela Dispenzieri: *State of the art*

OP 81. *N-terminal fragment of brain natriuretic peptide (NT-ProBNP) – a new response criterion in AL Amyloidosis*

A.D. Wechalekar, G. Merlini, J.D. Gillmore, P. Russo, H.J. Lachmann, S. Perlini, C.J. Whelan, P.N. Hawkins, G. Palladini  
(London, UK and Pavia, Italy)

OP 82. *B type natriuretic peptide (BNP) as a marker of cardiac response in AL amyloidosis*

G. Palladini, A. Foli, P. Milani, R. Albertini, G. Sarais, S. Perlini, P. Russo, L. Zenone Bragotti, F. Salinaro, L. Obici, R. Moratti, G.V. Melzi D'Eril, G. Merlini  
(Pavia and Milan, Italy)

OP 83. *Functional correlates of NT-proBNP response to therapy in cardiac AL amyloidosis*

S. Perlini, F. Musca, F. Salinaro, I. Fracchioni, G. Palladini, L. Obici, R. Albertini, R. Moratti, F. Lavatelli, G. Palladini, C. Rapezzi, G. Merlini  
(Pavia and Bologna, Italy)

OP 84. *Rapid hematologic and organ responses in patients with AL amyloid treated with bortezomib + melphalan and dexamethasone*

J. Zonder, V. Sanchowala, R. Snyder, J. Matous, H. Terebelo, N. Janakiraman, M. Mapara, S. Lalo, N. Tageja, C. Webb, D. Monsma, C. Sellers, J. Abrams, C. Gasparetto  
(Detroit, MI, Boston, MA, Southfield, MI, Pittsburgh, PA, Gran Rapids, MI, Durham, NC, USA)

OP 85. *Pomalidomide and dexamethasone for previously treated AL: a phase 2 study*

A. Dispenzieri, M.A. Gertz, S.R. Hayman, F. Buadi, S.K. Kumar, C. Reeder, S.R. Zeldenrust, S.V. Rajkumar, K. Detweiler-Short, J.A. Lust, T.E. Witzig, R.A. Kyle, P.R. Greipp, S.J. Russell, D. Dingli, J.B. Allred, K. Laumann, M. Thompson, R. Fonseca, L. Bergsagel, K. Stewart, J. Mikhael, V. Roy, M.Q. Lacy  
(Rochester, MN, Scottsdale, AZ, Jacksonville, FL, USA)

OP 86. *Lenalidomide in combination with melphalan and dexamethasone in patients with newly-diagnosed light-chain (AL)-amyloidosis: a multicenter phase I/II dose escalation study*

P. Moreau, A. Jaccard, L. Benboubker, B. Royer, X. Leleu, F. Bridoux, G. Salles, V. Leblond, M. Roussel, M. Alakl, O. Hermine, J.L. Harousseau, J.P. Fermand  
(Nantes, France; on behalf the IFM and MAG cooperative groups)

12:45–13:00 Steve Treon: *Perspectives*

**Wednesday,  
April 21  
13:00–14:30**

**Lunch and poster viewing – Business Meeting of the International Society of Amyloidosis**

**Wednesday,  
April 21  
14:30–18:45  
Hall Fori Imperiali**

**Plenary session open to Patients and their Families  
14:30–15:20 Plenary Session**

**Improving the care: therapies and networks**

Chairpersons: Domenica Taruscio and Robert Kyle

OP 87. *AMICA: an electronic patient record specifically designed for an amyloidosis network*

R. Ferrari, E. Caffi, S. Rubrichi, S. Quaglini, M. Stefanelli, P. Russo, G. Palladini, F. Lavatelli, G. Merlini  
(Pavia, Italy)

OP 88. *UK AL Amyloidosis Treatment Trial (UKATT) – a randomized study: lessons for future trial design*

J.D. Gillmore, K. Cocks, S.D.J. Gibbs, P. Sattianayagam, T. Lane, H.J. Lachmann, S. Schey, J. Cavenagh, H. Oakervee, G. Morgan, S. Bourne, E. Skinner, S. Bell, G. Booth, D.M. Foard, A. Mehta, P.N. Hawkins, A.D. Wechalekar  
(London, UK)

OP 89. *Trend toward improved day 100 and 2 year survival following stem cell transplantation for AL. A comparison before and after 2006*

M.A. Gertz, M.Q. Lacy, A. Dispenzieri, S. Kumar, S.R. Hayman, F. Buadi, D. Dingli, N. Leung, W.J. Hogan  
(Rochester, MN, USA)

OP 90. *Improved survival in light chain amyloidosis*

S. Kumar, A. Dispenzieri, M. Lacy, S. Hayman, F. Buadi, K. Short-Detweiler, S. Zeldenrust, N. Leung, D. Dingli, P. Greipp, J. Lust, S. Russel, R. Kyle, V. Rajkumar, M. Gertz  
(Rochester, MN, USA)

#### **15:20–15:40 Coffee break**

#### **15:40–18:15 Round Table: New trial design, orphan drugs, achievements and perspectives in systemic amyloidoses**

Panel Discussants: Domenica Taruscio, Franco Dammacco, Giovanni Gasbarrini, Robert Kyle, Martha Skinner and Sergio Dompé (President Farindustria) Representatives of Patients Associations: Muriel Finkel (USA), Pat Neely (Australia), Mary O'Donnell (USA), Rosa M. Turano (Italy)

#### **Meeting Summary**

15:40–15:50 Vittorio Bellotti: *Advancements in basic research in amyloidosis*

15:50–16:00 Bouke Hazenberg: *Advancements in non-AL amyloidosis*

16:00–16:10 Giampaolo Merlini: *Advancements in AL amyloidosis*

#### **Panel Discussion**

16:15–18:15 – Questions and Answers

#### **18:15–18:45 Concluding Lecture**

Mark Pepys: *Toward curing amyloidosis*

**Wednesday,**

**April 21**

**19:00**

**Hall Fori Imperiali**

#### **Closing ceremony**

Awards presentation

Announcement of the next Symposium

Farewell party

**Wednesday,**

**April 21**

**16:00–19:00**

#### **Poster viewing (refreshments available during poster viewing)**

*Poster Award Committee Nikhil Munshi (coordinator), Ute Hegenbart, Saji Kumar, Giovanni Palladini, Vaishali Santhorawala*

#### **Poster Group 14**

PP 152. *Long-term outcome after kidney transplantation with or without stem cell transplantation in immunoglobulin light chain (AL) amyloidosis*

N. Leung, S.M.S. Herrmann, A. Dispenzieri, S. Kumar, M.Q. Lacy, S.J. Russell, F.K. Buadi, S.R. Hayman, S.R. Zeldenrust, D. Dingli, P.G. Dean, M. Prieto, S. Nyberg, M. Stegall, F.C. Fervenza, M.A. Gertz  
(Rochester, MN, USA)

**Wednesday,  
April 21  
16:00–19:00**

- PP 153. *Salvage therapy with lenalidomide and dexamethasone (LDex) for patients with advanced refractory AL amyloidosis*  
G. Palladini, A. Foli, P. Milani, P. Russo, L. Zenone Bragotti, S. Perlini, V. Perfetti, F. Lavatelli, L. Obici, G. Merlini  
(Pavia, Italy)
- PP 154. *A phase II trial of cyclophosphamide, lenalidomide and dexamethasone (CLD) in previously treated patients with AL amyloidosis*  
P. Russo, G. Palladini, L. Zenone Bragotti, F. Musca, A. Foli, F. Lavatelli, V. Perfetti, M. Nuvolone, L. Obici, S. Perlini, G. Merlini  
(Pavia, Italy)
- PP 155. *Outcome of stem cell transplantation in patients with AL amyloidosis and autonomic neuropathy*  
D. Dingli, F.K. Buadi, A. Dispenzieri, S.R. Hayman, M.Q. Lacy, S. Kumar, D.A. Gastineau, W.J. Hogan, M.A. Gertz  
(Rochester, MN, USA)
- PP 156. *A phase II trial of lenalidomide, cyclophosphamide and dexamethasone (RCD) in patients with primary amyloidosis*  
F. Buadi, A. Dispenzieri, S. Hayman, J. Allred, K. Laumann, V. Roy, M. Lacy, M. Gertz, K. Detweiler-Short, A. Birgin, P. L. Bergsagel, D. Dingli, J. Mikhael, C. Reeder, K. Stewart, S. Zeldenrust, S.V. Rajkumar, S. Kumar  
(Rochester, MN, Scottsdale, AZ, USA)
- PP 157. *Cyclophosphamide–Bortezomib–Dexamethasone (CYBORD) is highly effective in producing rapid and complete responses in patients with AL amyloidosis not eligible for transplant*  
J. Mikhael, V.H. Jimenez-Zepeda, C.B. Reeder, A.K. Stewart, P. L. Bergsagel, R. Fonseca  
(Scottsdale, AZ, USA)
- PP 158. *Serum angiogenic cytokines in patients with AL amyloidosis*  
E. Kastiritis, M. Michail, E. Terpos, M. Roussou, M. Migkou, S. Delimpasi, E. Michalis, P. Repoussis, M.C. Kyrtsonis, M.A. Dimopoulos  
(Athens, Greece)
- PP 159. *Engraftment syndrome presenting as acute renal failure in light chain amyloidosis patients after autologous stem cell transplantation*  
N. Leung, M.A. Gertz, A. Dispenzieri, M.Q. Lacy, F. Buadi, S.R. Hayman, D. Dingli, W.J. Hogan, M.V. Irazabal, A. Eirin, S. Kumar  
(Rochester, MN, USA)
- PP 160. *Nutritional status and quality of life in outpatients with systemic immunoglobulin light-chain amyloidosis (AL) at diagnosis*  
R. Caccialanza, G. Palladini, C. Klersy, C. Bonardi, B. Cameletti, E. Cereda, P. Russo, A. Foli, L. Zenone Bragotti, G. Merlini  
(Pavia, Italy)
- PP 161. *Differences in clinical presentation and outcomes of patients with vascular limited light chain amyloidosis (AL) versus diffuse*  
N. Leung, M.V. Irazabal, A. Eirin, M.Q. Lacy, A. Dispenzieri, F.K. Buadi, S.R. Zeldenrust, S.R. Hayman, S. Kumar, S.J. Russell, R.A. Kyle, M. Ramirez-Alvarado, S. Sethi, S.B. Erickson, F.C. Ferverza, M.A. Gertz  
(Rochester, MN, USA)
- PP 162. *Transient elastography (FibroScan®) for non-invasive assessment of liver amyloidosis*  
A. Jaccard, A. Cypierre, A. Rousseau, F. Yagoubi, J. Abraham, A. Lefebvre, V. Loustaud-Ratti  
(Limoges, France)

**Wednesday,  
April 21  
16:00–19:00**

- PP 163. *Interphase and cytoplasmic-Ig FISH in 45 patients with primary amyloidosis (AL): which technique is the most effective in revealing chromosomal lesions?*  
P. Bernasconi, C. Calvello, I. Dambruoso, M. Boni, V. Perfetti, G. Palladini, A. Foli, L. Obici, G. Merlini  
(Pavia, Italy)
- PP 164. *Clinical features and treatment response of AL amyloidosis diagnosed in patients with myeloma*  
S. Madan, A. Dispenzieri, M. Lacy, F. Buadi, S. Hayman, K. Detweiler-Short, S. Zeldenrust, D. Dingli, P. Greipp, S. Russell, J. Lust, R. Kyle, S.V. Rajkumar, M. Gertz, S. Kumar  
(Rochester, MN, USA)
- PP 165. *Approach to diagnosis in systemic amyloidosis: initial findings and time from symptoms onset to diagnosis*  
M. Di Girolamo, D. Monn, M.R. Pirro, M. Nowakowski  
(Rome and Melfi, Italy)
- PP 166. *Severe intrahepatic cholestasis in systemic AL amyloidosis: early reversal after bortezomib therapy*  
N. Paudice, S. Farsetti, L. Caroti, G. Ciuti, A. Tempestini, F. Perfetto, F. Bergesio (Florence, Italy)
- PP 167. *Amyloidosis presenting with Fabry disease*  
P. Tansinda, L. Manenti, M. Gregorini, M. Foroni, S. Pasquali  
(Liverpool, UK and Reggio Emilia, Italy)
- PP 168. *Clues to diagnosis of AL-amyloidosis: two cases*  
H. Akar, O. Cengiz, H. Yuceturk, H. Akdam, I. Meteoglu, Y. Yavasoglu, D.F. Kacar, G. Kadikoylu, Y. Yenicerioglu, Z. Bolaman  
(Aydin, Turkey)

#### **Poster Group 15**

- PP 169. *Do the immune modulatory drugs (IMiDs<sup>®</sup>) affect levels of troponin T (TnT) and N-terminal brain natriuretic peptide (NTproBNP) in patients with immunoglobulin light chain amyloidosis (AL)?*  
A. Dispenzieri, S.K. Kumar, M.Q. Lacy, R.A. Kyle, N. Leung, S.R. Zeldenrust, S.R. Hayman, F. Buadi, P.R. Greipp, S.R. Russell, K. Detweiler-Short, D. Dingli, J.A. Lust, S.V. Rajkumar, M.A. Gertz  
(Rochester, MN, USA)
- PP 170. *Rise in serum NT pro-BNP associated with chemotherapy in patients with AL amyloidosis: Implications for organ response assessment*  
S.D.J. Gibbs, P.T. Sattianayagam, C.J. Whelan, M. De Cruz, J.M. Abreu, J.H. Pinney, B. Pawarova, N.L. Wassef, T. Lane, H.J. Lachmann, J.D. Gillmore, P.N. Hawkins, A.D. Wechalekar  
(London, UK)
- PP 171. *Serum immunoglobulin free light chain in AL amyloidosis: prognostic value and correlations with clinical features*  
S. Kumar, A. Dispenzieri, R. Clark, D. Larson, C. Colby, S. Zeldenrust, M. Lacy, S. Hayman, F. Buadi, N. Leung, M. Ramirez-Alvarado, R.A. Kyle, J.A. Katzmman, S.V. Rajkumar, M.A. Gertz  
(Rochester, MN, USA)
- PP 172. *Modified high-dose melphalan and stem cell transplantation for AL amyloidosis: Experience of 14 years*  
V. Sancharawala, D.C. Seldin, K. Quillen, K.T. Finn, J.M. Sloan, N.T. Andrea, G. Doros, J.L. Berk, L.M. Dember, A. Segal, F.L. Ruberg, H. Meier-Ewert, J. Weisman, M. Skinner  
(Boston, MA, USA)

**Wednesday,  
April 21  
16:00–19:00**

- PP 173. *Changes in serum free light chain rather than intact monoclonal immunoglobulin levels predict outcome with therapy in patients with light chain amyloidosis*  
S. Kumar, M. Gertz, M. Lacy, S. Hayman, F. Buadi, S. Zeldenrust, M. Ramirez-Alvarado, N. Leung, A. Dispenzieri  
(Rochester, MN, USA)
- PP 174. *The variability of SPEP M-spike, serum FLC quantitation, and UPEP M-spike in monoclonal gammopathies*  
J.A. Katzmann, M.R. Snyder, D.R. Larson, S.V. Rajkumar, R.A. Kyle, A. Dispenzieri  
(Rochester, MN, USA)
- PP 175. *A novel prognostic staging system for light chain amyloidosis (AL)*  
S. Kumar, A. Dispenzieri, M. Lacy, S. Hayman, F. Buadi, S. Zeldenrust, N. Leung, M. Ramirez-Alvarado, R.A. Kyle, S.V. Rajkumar, M.A. Gertz  
(Rochester, MN, USA)
- PP 176. *Outcomes with HDT and PB Stem Cell Transplantation for AL amyloidosis with cardiac involvement*  
S. Madan, S. Kumar, A. Dispenzieri, M.Q. Lacy, S. Hayman, F. Buadi, D. Dingli, M.A. Gertz  
(Rochester, MN, USA)
- PP 177. *The Florence Register of amyloidosis : 20 years experience in the diagnosis and treatment of the disease in the Florence district area*  
A. Cania, F. Bergesio, G. Curciarello, F. Perfetto, A.M. Ciciani, S. Nigrelli, B. Minuti, A.L. Caldini, S. Di Lollo, C. Nozzoli, M. Salvadori  
(Florence, Italy)
- PP 178. *Endoscopic management of laryngo-tracheobronchial amyloidosis: a series of eight patients*  
L. Firrisi, L. de Campora  
(Rome, Italy)
- PP 179. *Renal papillary necrosis in systemic amyloidoses*  
H. Hamberg, G.T. Westermark, E. Davey, P. Westermark  
(Uppsala, Sweden)
- PP 180. *A long-term follow-up study of three AH amyloidosis patients*  
M. Yazaki, N. Katoh, D. Miyazaki, M. Matsuda, S. Ikeda, Y. Takenaka  
(Matsumoto, Japan)
- PP 181. *Efficacy of bortezomib (B) plus dexamethasone (D) in a patient with AL amyloidosis resistant to melphalan (M) and dexamethasone*  
A. Andriani, N. Villivà, S. Felici, C. Gualandi, G. Palladini  
(Rome and Pavia, Italy)

#### **Poster Group 16**

- PP 182. *Light chain deposition disease (LCDD): a case series of 24 patients*  
S.D.J. Gibbs, J.H. Pinney, P.T. Sattianayagam, A.D. Wechalekar, T. Lane, D.M. Rowczenio, M. Offer, J.A. Gilbertson, T. Hunt, P.N. Hawkins, J.D. Gillmore, H.J. Lachmann  
(London, UK)
- PP 183. *Bortezomib and high dose melphalan with stem cell transplantation for AL amyloidosis: Pilot study*  
V. Sancharawala, K. Quillen, J.M. Sloan, N.T. Andrea, K.T. Finn, D.C. Seldin  
(Boston, MA, USA)
- PP 184. *Treatment of light chain amyloidosis patients with lenalidomide and dexamethasone after failure of melphalan-containing chemotherapies*  
U. Hegenbart, T. Bochtler, S. Dietrich, A.D. Ho, S. Schönland  
(Heidelberg, Germany)

**Wednesday,  
April 21  
16:00–19:00**

- PP 185. *Early serum free light chain responses following HDM/SCT for AL amyloidosis*  
S. Girnius, F. Tsai, D.C. Seldin, K. Quillen, K.T. Finn, N.T. Andrea, J.M. Sloan, M. Skinner, V. Sanchorawala  
(Boston, MA, USA)
- PP 186. *Serum immunoglobulin heavy/light chain ratios (HevyLite) in patients with systemic AL amyloidosis*  
A.D. Wechalekar, S. Harding, H.J. Lachmann, J.D. Gillmore, N.L. Wassef, M. Thomas, S.D.J. Gibbs, P. Sattianayagam, C.J. Whelan, A.R. Bradwell, P.N. Hawkins  
(London, UK)
- PP 187. *Outcome of patients with AL amyloidosis who do not achieve hematologic complete response after autologous SCT: Results in a series of 454 patients*  
M.T. Cibeira, V. Sanchorawala, D.C. Seldin, M. Sloan, J. Blade, M. Skinner  
(Boston, MA, USA and Barcelona, Spain)
- PP 188. *Hepatocyte Growth Factor (HGF) measurement in AL amyloidosis*  
E. Desport, J. Abraham, B. Marin, S. Bender, C. Lacombe, F. Yagoubi, D. Lavergne, F. Bridoux, A. Jaccard  
(Limoges and Poitiers, France)
- PP 189. *Effectiveness of second line treatment in AL amyloidosis patients refractory to M-Dex*  
A. Jaccard, J. Abraham, H. Debarri, A. Penot, E. Desport, C. Aguilar, D. Lavergne, F. Auroy, X. Leleu, A. Goldstein, B. Kolb, F. Bridoux, J.P. Fermand, V. Leblond  
(Limoges, Lille, Poitiers, Le Mans and Reims, France)
- PP 190. *Inaugural light-chain amyloid polyneuropathy: clinical presentation and course, a monocentric study of 24 patients*  
D. Adams, P. Lozeron, V. Ribrag, C. Denier, O. Fagniez, M. Theaudin, K. Rerat, J.H. Bourhis, B. Ducot, C. Lacroix  
(Le Kremlin Bicêtre, France)
- PP 191. *Unraveling the clonal B cell disease underlying localized AL Amyloidosis*  
T. Hunt, J.A. Gilbertson, H.J. Lachmann, J.D. Gillmore, S.D.J. Gibbs, P.T. Sattianayagam, C.J. Whelan, P.N. Hawkins, A.D. Wechalekar  
(London, UK)

**Poster Group 17**

- PP 192. *Melphalan, lenalidomide, and dexamethasone combination therapy in patients with AL amyloidosis*  
J.M. Sloan, V. Sanchorawala, S. Girnius, K.T. Finn, D.C. Seldin  
(Boston, MA, USA)
- PP 193. *Expression of Cancer Testis (CT) antigens in bone marrow of patients with AL amyloidosis*  
M. Rosenzweig, H. Landau, A.A. Jungbluth, N. Hanson, D. Frosina, M. Arcila, R. Comenzo, G. Koehne  
(New York, NY and Boston, MA, USA)
- PP 194. *Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis*  
W. Lamm, W. Willenbacher, A. Lang, N. Zojer, E. Müldür, H. Ludwig, C.C. Zielinski, J. Drach  
(Wien, Innsbruck, and Feldkirch, Austria)
- PP 195. *Bortezomib in systemic AL Amyloidosis: a single center experience*  
D. Coriu, S. Badelita, R. Talmaci, C. Dobrea, M. Dogaru, D. Ostroveanu, M. Crisan  
(Bucharest, Romania)

**Wednesday,  
April 21  
16:00–19:00**

- PP 196. *Correlation between serum levels of free light chain and circulating cytokines in a patient with AL cardiac amyloidosis*  
F. Saltarelli, M.P. Bianchi, A. Moscetti, G. Ferranti, F. Capogreco, M.T. Corsetti, G. Salerno, P. Cardelli, G. La Verde  
(Rome, Italy)
- PP 197. *Hairy cell leukemia and AL amyloidosis*  
M.D. Benson, G. Kramer, R. Abonour  
(Indianapolis, IN, USA)
- PP 198. *Perinasal dermatitis due to a local monoclonal plasmocytoma with vicinal AL $\lambda$  amyloid*  
M. Laimer, H. Hintner, R.P. Linke  
(Salzburg, Austria and Martinsried, Germany)
- PP 199. *AL amyloidosis: different therapeutical approaches for long survivals*  
A. Moscetti, F. Saltarelli, M.P. Bianchi, B. Monarca, L. De Biase, P. Menè, B. Veggia, V. Naso, G. La Verde  
(Rome, Italy)
- PP 200. *Two cases of localized amyloidosis*  
A. Moscetti, F. Saltarelli, M.P. Bianchi, B. Monarca, G. Bandiera, L. De Biase, G. La Verde  
(Rome, Italy)
- PP 201. *Serum Vascular Endothelial Growth Factor (VEGF) in the differential diagnosis of amyloid neuropathy and POEMS syndrome*  
F. Adami, C. Briani, L. Dorotea, G. Binotto, G.M. Fabrizi, G. Semenzato  
(Padova and Verona, Italy)

#### **Poster Group 18**

- PP 202. *Diagnostic and prognostic relevance of B-type natriuretic peptide (BNP) and N-terminal proBNP in patients with AL amyloidosis and renal failure*  
G. Palladini, S. Perlini, A. Foli, P. Russo, R. Albertini, L. Zenone Bragotti, F. Lavatelli, L. Obici, G. Sarais, R. Moratti, G. Merlini  
(Pavia, Italy)
- PP 203. *Pathogenetic associations of plasma cell cyclin D1 overexpression in systemic AL amyloidosis*  
P. Zhou, L.K. Iyer, H. Hassoun, J. Hoffman, H. Landau, R.L. Comenzo  
(Boston, MA, Weston, FL and New York, NY, USA)
- PP 204. *Liver failure in association with hepatic amyloidosis and the role of liver transplantation; the King's College Hospital experience*  
A.J. Stangou, M. Rela, M. Monaghan, C.J. Mathias, G. Mufti, N. Heaton, J. O'Grady  
(London, UK)
- PP 205. *An underdiagnosed disease? High prevalence of senile amyloidosis in a cardiac amyloid programme*  
J.L. Kruger, R.H. Falk  
(Boston, MA, USA)
- PP 206. *Assessment of a monoclonal antibody-based free light chain ELISA and the polyclonal antibody-based Freelite assay in AL amyloidosis*  
P. Mollee, J. Tate, D. Weiss, A. Solomon  
(Brisbane, Australia and Knoxville, TN, USA)
- PP 207. *Results of autologous stem cell transplantation for AL amyloidosis in one Czech centre*  
R. Rysava, J. Straub, B. Vackova, J. Koren, M. Trníný, Z. Potysova, I. Spicka  
(Prague, CZ)
- PP 208. *Peripheral blood autologous stem cell transplantation in AL-amyloidosis patients: the impact of renal insufficiency*  
S. Pasquali, M. Mandreoli, R. Rustichelli, L. DeSanctis, L. Manenti, A. Santoro  
(Reggio Emilia, Italy)



**Wednesday,  
April 21  
16:00–19:00**

PP 209. *Liver involvement with rapidly progressive course in AL amyloidosis (AL): distinguishing features at presentation. Experience of a single center*  
L. Econimo, G. Gregorini, L. Biasi, G. Mazzola, M. Mendeni,  
K. Presteni, G. Jeannin, G. Cancarini  
(Brescia, Italy)

**Poster Group 19**

- PP 210. *AL amyloidosis in the Central Nervous System (CNS)*  
M.D. Benson, T.C. Witt, J. Bonin, B. Matthews, R. Abonour  
(Indianapolis, IN, USA)
- PP 211. *Bortezomib (Velcade) treatment of AL amyloidosis: Indiana University experience*  
R. Abonour, G. Kramer, A. Suvannasankha, M.D. Benson  
(Indianapolis, IN, USA)
- PP 212. *Regression of gastroduodenal amyloid deposits after chemotherapies in AL amyloidosis*  
N. Katoh, A. Tsuchiya-Suzuki, M. Matsuda, S. Ikeda  
(Matsumoto, Japan)
- PP 213. *AL amyloidosis is a rare complication of Waldenström's macroglobulinemia*  
F. Merchionne, P. Procaccio, F. Dammacco  
(Bari, Italy)
- PP 214. *A historic cerebral amyloidoma classified retrospectively as AL $\lambda$ -type*  
A. Jährig, F.W. Spaar, R. Schröder, R.P. Linke  
(Martinsried, Göttingen and Cologne, Germany)
- PP 215. *A case of localized cerebral light-chain amyloidosis with disseminated periventricular pattern*  
T. Bochtler, U. Hegenbart, S. Schönland, G. Hermann, M. Deckert,  
S. Rohde, A. Ho, E. Hund  
(Heidelberg, Germany)
- PP 216. *A case of AL amyloidosis associated with IgD MM: clinical and laboratory findings, and outcome*  
R. Rizzi, R. Miccolis, E. Rinaldi, B. Bonerba, M. Rossini, C. Manno,  
P. Curci, G. Specchia, V. Liso  
(Bari, Italy)
- PP 217. *Recurrent haemorrhagic bullae of oral cavity and cranial nerve palsy: two rare manifestations at the onset of AL amyloidosis in the same patient*  
G. Gregorini, G. Jeannin, L. Econimo, L. Morassi, P. Faggiano,  
M. Nardi, G. Cancarini  
(Brescia, Italy)
- PP 218. *A case report of kappa L-chain primary nodular lung amyloidosis*  
B. Moscatelli, G.B. Capocchetta, P. Anselmi, M. Di Girolamo,  
D. Campagna  
(Rome, Italy)
- PP 219. *Quick response to bortezomib plus dexamethasone in a patient with AL amyloidosis in first relapse*  
A. Moscetti, F. Saltarelli, M.P. Bianchi, B. Monarca, L. De Biase,  
R. Porrini, G. Antolino, G. La Verde  
(Rome, Italy)
- PP 220. *Modern diagnostic and therapeutical approach to cardiac AL amyloidosis: lessons from a clinical case*  
A. Giannoni, G. Aquaro, G. Vergaro, A. Valleggi, L.E. Pastormerlo,  
M. Fontana, R. Poletti, E. Benedetti, M. Petrini, C. Passino, G. Merlini,  
M. Emdin  
(Pisa and Pavia, Italy)